Document:

Exhibit 10.1

Exhibit 10.1

FORM OF

CONTINGENT VALUE RIGHTS AGREEMENT

by and between

CELGENE CORPORATION

and

[TRUSTEE]

Dated as of [•], 2010

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION
	 	 	2	 
	 
	 	 	 	 
	Section 1.1 Definitions
	 	 	2	 
	Section 1.2 Compliance and Opinions
	 	 	13	 
	Section 1.3 Form of Documents Delivered to Trustee
	 	 	14	 
	Section 1.4 Acts of Holders
	 	 	14	 
	Section 1.5 Notices, etc., to Trustee and Company
	 	 	15	 
	Section 1.6 Notice to Holders; Waiver
	 	 	16	 
	Section 1.7 Conflict with Trust Indenture Act
	 	 	16	 
	Section 1.8 Effect of Headings and Table of Contents
	 	 	16	 
	Section 1.9 Benefits of Agreement
	 	 	16	 
	Section 1.10 Governing Law
	 	 	16	 
	Section 1.11 Legal Holidays
	 	 	17	 
	Section 1.12 Separability Clause
	 	 	17	 
	Section 1.13 No Recourse Against Others
	 	 	17	 
	Section 1.14 Counterparts
	 	 	17	 
	Section 1.15 Acceptance of Trust
	 	 	17	 
	 
	 	 	 	 
	ARTICLE 2 SECURITY FORMS
	 	 	17	 
	 
	 	 	 	 
	Section 2.1 Forms Generally
	 	 	17	 
	 
	 	 	 	 
	ARTICLE 3 THE SECURITIES
	 	 	18	 
	 
	 	 	 	 
	Section 3.1 Title and Terms
	 	 	18	 
	Section 3.2 Registrable Form
	 	 	20	 
	Section 3.3 Execution, Authentication, Delivery and Dating
	 	 	20	 
	Section 3.4 Temporary Securities
	 	 	20	 
	Section 3.5 Registration, Registration of Transfer and Exchange
	 	 	21	 
	Section 3.6 Mutilated, Destroyed, Lost and Stolen Securities
	 	 	22	 
	Section 3.7 Payments with respect to CVR Certificates
	 	 	22	 
	Section 3.8 Persons Deemed Owners
	 	 	22	 
	Section 3.9 Cancellation
	 	 	22	 

 

i

 

	 	 	 	 	 
	ARTICLE 4 THE TRUSTEE
	 	 	23	 
	 
	 	 	 	 
	Section 4.1 Certain Duties and Responsibilities
	 	 	23	 
	Section 4.2 Certain Rights of Trustee
	 	 	23	 
	Section 4.3 Notice of Default
	 	 	24	 
	Section 4.4 Not Responsible for Recitals or Issuance of Securities
	 	 	25	 
	Section 4.5 May Hold Securities
	 	 	25	 
	Section 4.6 Money Held in Trust
	 	 	25	 
	Section 4.7 Compensation and Reimbursement
	 	 	25	 
	Section 4.8 Disqualification; Conflicting Interests
	 	 	26	 
	Section 4.9 Corporate Trustee Required; Eligibility
	 	 	26	 
	Section 4.10 Resignation and Removal; Appointment of Successor
	 	 	26	 
	Section 4.11 Acceptance of Appointment of Successor
	 	 	27	 
	Section 4.12 Merger, Conversion, Consolidation or Succession to Business
	 	 	28	 
	Section 4.13 Preferential Collection of Claims Against Company
	 	 	28	 
	 
	 	 	 	 
	ARTICLE 5 HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY
	 	 	28	 
	 
	 	 	 	 
	Section 5.1 Company to Furnish Trustee Names and Addresses of Holders
	 	 	28	 
	Section 5.2 Preservation of Information; Communications to Holders
	 	 	29	 
	Section 5.3 Reports by Trustee
	 	 	29	 
	Section 5.4 Reports by Company
	 	 	29	 
	 
	 	 	 	 
	ARTICLE 6 AMENDMENTS
	 	 	30	 
	 
	 	 	 	 
	Section 6.1 Amendments Without Consent of Holders
	 	 	30	 
	Section 6.2 Amendments with Consent of Holders
	 	 	31	 
	Section 6.3 Execution of Amendments
	 	 	31	 
	Section 6.4 Effect of Amendments; Notice to Holders
	 	 	32	 
	Section 6.5 Conformity with Trust Indenture Act
	 	 	32	 
	Section 6.6 Reference in Securities to Amendments
	 	 	32	 
	 
	 	 	 	 
	ARTICLE 7 COVENANTS
	 	 	32	 
	 
	 	 	 	 
	Section 7.1 Payment of Amounts, if any, to Holders
	 	 	32	 
	Section 7.2 Maintenance of Office or Agency
	 	 	33	 
	Section 7.3 Money for Security Payments to Be Held in Trust
	 	 	33	 
	Section 7.4 Certain Purchases and Sales
	 	 	34	 

 

ii

 

	 	 	 	 	 
	Section 7.5 Books and Records
	 	 	34	 
	Section 7.6 Audits
	 	 	34	 
	Section 7.7 Listing of CVRs
	 	 	35	 
	Section 7.8 Conflicting Arrangements
	 	 	36	 
	Section 7.9 Product Transfer
	 	 	36	 
	Section 7.10 Milestones
	 	 	36	 
	Section 7.11 Product Sale and Development
	 	 	36	 
	Section 7.12 Notice of Default
	 	 	37	 
	Section 7.13 Confidentiality
	 	 	37	 
	Section 7.14 Non-Use of Name
	 	 	37	 
	 
	 	 	 	 
	ARTICLE 8 REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT
	 	 	38	 
	 
	 	 	 	 
	Section 8.1 Event of Default Defined; Waiver of Default
	 	 	38	 
	Section 8.2 Collection by the Trustee; the Trustee May Prove Payment Obligations
	 	 	39	 
	Section 8.3 Application of Proceeds
	 	 	41	 
	Section 8.4 Suits for Enforcement
	 	 	41	 
	Section 8.5 Restoration of Rights on Abandonment of Proceedings
	 	 	41	 
	Section 8.6 Limitations on Suits by Holders
	 	 	42	 
	Section 8.7 Unconditional Right of Holders to Institute Certain Suits
	 	 	42	 
	Section 8.8  Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default 
	 	 	42	 
	Section 8.9 Control by Holders
	 	 	42	 
	Section 8.10 Waiver of Past Defaults
	 	 	43	 
	Section 8.11 The Trustee to Give Notice of Default, But May Withhold in Certain
Circumstances 
	 	 	43	 
	Section 8.12 Right of Court to Require Filing of Undertaking to Pay Costs
	 	 	43	 
	 
	 	 	 	 
	ARTICLE 9 CONSOLIDATION, MERGER, SALE OR CONVEYANCE
	 	 	44	 
	 
	 	 	 	 
	Section 9.1 Company May Consolidate, etc., on Certain Terms
	 	 	44	 
	Section 9.2 Successor Person Substituted
	 	 	44	 
	Section 9.3 Opinion of Counsel to the Trustee
	 	 	45	 
	Section 9.4 Successors
	 	 	45	 

 

iii

 

	 	 	 	 	 
	ARTICLE 10 SUBORDINATION
	 	 	45	 
	 
	 	 	 	 
	Section 10.1 Agreement to Subordinate
	 	 	45	 
	Section 10.2 Liquidation; Dissolution; Bankruptcy
	 	 	45	 
	Section 10.3 Default on Senior Obligations
	 	 	46	 
	Section 10.4 When Distribution Must Be Paid Over
	 	 	46	 
	Section 10.5 Notice by Company
	 	 	47	 
	Section 10.6 Subordination Effective Notwithstanding
Deficiencies with Respect to Senior
Obligations; Waiver of Right to Contest
Senior Obligation; Reinstatement of Subordination
Provisions
	 	 	47	 
	Section 10.7 Subrogation
	 	 	48	 
	Section 10.8 Relative Rights
	 	 	48	 
	Section 10.9 Subordination May Not Be Impaired by Company
	 	 	48	 
	Section 10.10 Distribution or Notice to Representative
	 	 	48	 
	Section 10.11 Rights of the Trustee
	 	 	49	 
	Section 10.12 Authorization to Effect Subordination
	 	 	49	 
	Section 10.13 Amendments
	 	 	49	 
	 
	 	 	 	 
	ARTICLE 11 REDEMPTION OF SECURITIES
	 	 	49	 
	 
	 	 	 	 
	Section 11.1 Notice to Trustee
	 	 	49	 
	Section 11.2 Selection of Securities to be Redeemed
	 	 	49	 
	Section 11.3 Notice of Redemption
	 	 	50	 
	Section 11.4 Effect of Notice of Redemption
	 	 	50	 
	Section 11.5 Deposit of Redemption Price
	 	 	51	 
	Section 11.6 Optional Redemption by the Company
	 	 	51	 

 

	 	 	 
	Annex A
— Form of CVR Certificate

	 
	Note:	 	This table of contents shall not, for any purpose, be deemed to
be a part of this CVR Agreement.

 

iv

 

Reconciliation and tie between Trust Indenture Act of 1939 and Contingent Value Rights Agreement,
dated as of [•], 2010. [to be updated]

	 	 	 	 
	Trust Indenture Act Section	 	Agreement Section
	 
	Section 310 (a)(1)
	 	 	4.9
	(a)(2)
	 	 	4.9
	(a)(3)
	 	Not Applicable
	(a)(4)
	 	Not Applicable
	(a)(5)
	 	 	4.9
	(b)
	 	 	4.8, 4.10
	 
	 	 	 
	Section 311 (a)
	 	 	4.13(a)
	(b)
	 	 	4.13(a)
	 
	 	 	 
	Section 312 (a)
	 	 	5.1, 5.2(a)
	(b)
	 	 	5.2(b)

	(c)
	 	 	5.2(c)
	 
	 	 	 
	Section 313 (a)
	 	 	5.3(a)
	(b)
	 	 	5.3(a)
	(c)
	 	 	5.3(a)
	(d)
	 	 	5.3(b)
	 
	 	 	 
	Section 314 (a)
	 	 	5.4
	(b)
	 	Not Applicable
	(c)(1)
	 	 	1.2(a)
	(c)(2)
	 	 	1.2(a)
	(c)(3) 
	 	  Not Applicable
	(d)
	 	Not Applicable

	(e)
	 	 	1.2(b)
	 
	 	 	 
	Section 315 (a)
	 	 	4.1(a), 4.1(b)
	(b)
	 	 	8.11
	(c)
	 	 	4.1(a)
	(d)
	 	 	4.1(c)
	(d)(1)
	 	 	4.1(a), 4.1(b)
	(d)(2)
	 	4.1(c)(ii)
	(d)(3)
	 	4.1(c)(iii)
	(e)
	 	 	8.12

 

v

 

	 	 	 	 
	Trust Indenture Act Section	 	Agreement Section
	 
	Section 316 (a)(last sentence)
	 	 	1.15
	(a)(1)(A)
	 	 	8.9
	(a)(1)(B)
	 	 	8.10
	(a)(2)
	 	Not Applicable
	(b)
	 	 	8.7
	Section 317 (a)(1)
	 	 	8.2
	(a)(2)
	 	 	                          8.2
	(b)
	 	 	7.3
	Section 318 (a)
	 	 	1.7

 

	 	 	 
	Note: 	 	This reconciliation and tie shall not, for any purpose, be deemed to be a part of this
CVR Agreement.

 

vi 

 

THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [•], 2010 (this “CVR Agreement”),
by and between Celgene Corporation, a Delaware corporation (the “Company”), and [•], a
national banking association, as trustee (the “Trustee”), in favor of each person who from
time to time holds one or more Contingent Value Rights (the “Securities” or “CVRs”)
to receive cash payments in the amounts and subject to the terms and conditions set forth herein.

W I T N E S S E T H:

WHEREAS, this CVR Agreement is entered into pursuant to the Agreement and Plan of Merger,
dated as of June 30, 2010 (as amended prior to the effective time thereof, the “Merger
Agreement”), by and among the Company, Artistry Acquisition Corp., a Delaware corporation and
wholly owned Subsidiary of the Company (“Sub”), and Abraxis BioScience, Inc., a Delaware
corporation (“Abraxis”);

WHEREAS, pursuant to the Merger Agreement, Sub will merge with and into Abraxis (the
“Merger”), with Abraxis being the surviving corporation in the Merger and becoming a
wholly-owned Subsidiary of the Company;

WHEREAS, in the Merger, one (1) CVR will be issued in respect of (a) each share of common
stock, par value $0.001 per share, of Abraxis (“Common Stock”) (other than shares of Common
Stock that are Excluded Company Shares or Dissenting Company Shares) (all as defined in the Merger
Agreement), (b) each share of Common Stock underlying each Option (as defined in the Merger
Agreement) having an exercise price that is less than or equal to the Per Share Amount (as defined
in the Merger Agreement), (c) each share of Common Stock underlying each Option having an exercise
price that is greater than the Per Share Amount, if such Option is exercised and settled in
accordance with the Merger Agreement, (d) each SAR (as defined in the Merger Agreement) having a
base appreciation amount that is less than or equal to the Per Share Amount, (e) each SAR having a
base appreciation amount that is greater than the Per Share Amount, if such SAR is exercised and
settled in accordance with the Merger Agreement, and (f) each RSU (as defined in the Merger
Agreement), in each case, outstanding immediately prior to the Effective Time (as defined in the
Merger Agreement); and

WHEREAS, a registration statement on Form S-4 (No. 333-[•]) (the “Registration
Statement”) with respect to the CVRs has been prepared and filed by the Company with the
Commission (as defined below) and has become effective in accordance with the Securities Act of
1933, as amended (the “Securities Act”).

NOW, THEREFORE, in consideration of the foregoing premises and the consummation of the
transactions contemplated by the Merger Agreement, it is covenanted and agreed, for the equal and
proportionate benefit of all Holders of the Securities, as follows:

 

1

 

ARTICLE 1

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION

Section 1.1 Definitions. For all purposes of this CVR Agreement, except as otherwise
expressly provided or unless the context otherwise requires:

(a) the terms defined in this Article have the meanings assigned to them in this Article, and
include the plural as well as the singular;

(b) all accounting terms used herein and not expressly defined herein shall, except as
otherwise noted, have the meanings assigned to such terms in accordance with applicable Accounting
Standards, where “Accounting Standards” means (A) GAAP (United States Generally Accepted
Accounting Principles); or (B) to the extent that the Company adopts International Financial
Reporting Standards (IFRS), then “Accounting Standards” means International Financial
Reporting Standards (IFRS), in either case consistently applied;

(c) all capitalized terms used in this CVR Agreement without definition shall have the
respective meanings ascribed to them in the Merger Agreement;

(d) all other terms used herein which are defined in the Trust Indenture Act (as defined
herein), either directly or by reference therein, have the respective meanings assigned to them
therein; and

(e) the words “herein,” “hereof” and “hereunder” and other words of
similar import refer to this CVR Agreement as a whole and not to any particular Article, Section or
other subdivision.

“Affiliate” of any specified Person means any other Person directly or indirectly
controlling or controlled by or under direct or indirect common control with such specified Person.
For the purposes of this definition, “control” when used with respect to any specified Person
means the power to direct the management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise; and the terms
“controlling” and “controlled” have meanings correlative to the foregoing.

“Board of Directors” means the board of directors of the Company or any other body
performing similar functions, or any duly authorized committee of that board.

“Board Resolution” means a copy of a resolution certified by the Secretary or an
Assistant Secretary of the Company, to have been duly adopted by the Board of Directors and to be
in full force and effect on the date of such certification, and delivered to the Trustee.

“Business Day” means any day (other than a Saturday or a Sunday) on which banking
institutions in The City of New York, New York are not authorized or obligated by Law or executive
order to close and, if the CVRs are listed on a national securities exchange, electronic trading
network or other suitable trading platform, such exchange, electronic network or other trading
platform is open for trading.

“Call Notice” shall have the meaning set forth in Section 11.3 of this CVR Agreement.

“Combination Product” means any product that comprises a Product sold in conjunction
with another active component (whether packaged together or in the same therapeutic formulation or
otherwise) or service.

 

2

 

“Commission” means the Securities and Exchange Commission, as from time to time
constituted, created under the Exchange Act (as defined herein), or if at any time after the
execution of this instrument such Commission is not existing and performing the duties now assigned
to it under the Trust Indenture Act, then the body performing such duties at such time.

“Common Stock” shall have the meaning set forth in the Recitals of this CVR Agreement.

“Company” means the Person (as defined herein) named as the “Company” in the first
paragraph of this CVR Agreement, until a successor Person shall have become such pursuant to the
applicable provisions of this CVR Agreement, and thereafter “Company” shall mean such successor
Person. To the extent necessary to comply with the requirements of the provisions of Trust
Indenture Act Sections 310 through 317, inclusive, to the extent that they are applicable to the
Company, the term “Company” shall include any other obligor with respect to the Securities for the
purposes of complying with such provisions.

“Company Request” or “Company Order” means a written request or order signed
in the name of the Company by the chairman of the Board of Directors or the president or any vice
president, the controller or assistant controller and the treasurer or assistant treasurer or the
secretary or any assistant secretary, and delivered to the Trustee.

“Confidential Information” shall have the meaning set forth in Section 7.13 of this
CVR Agreement.

“Consent and Purchase Offer” shall have the meaning set forth in Section 11.1 of this
CVR Agreement.

“Corporate Trust Office” means the office of the Trustee at which at any particular
time its corporate trust business shall be principally administered, which office at the date of
execution of this CVR Agreement is located at [•].

“CVRs” shall have the meaning set forth in the Preamble of this CVR Agreement.

“CVR Agreement” means this instrument as originally executed and as it may from time
to time be supplemented or amended pursuant to the applicable provisions hereof.

“CVR Certificate” means a certificate representing any of the CVRs.

“CVR Payment” means any Net Sales Payment and any Milestone Payment.

“CVR Shortfall” shall have the meaning set forth in Section 7.6(b) of this CVR
Agreement.

“Default Interest Rate” means a rate equal to the sum of three percent (3%) plus the
prime rate of interest quoted in the Money Rates section of The Wall Street Journal (New York
Edition), or similar reputable data source, calculated daily on the basis of a three hundred
sixty-five (365) day year or, if lower, the highest rate permitted under applicable Law.

 

3

 

“Diligent Efforts” means, with respect to any Product, efforts of a Person to carry
out its obligations in a diligent manner using such effort and employing such resources normally
used by such Person in the exercise of its reasonable business discretion relating to the research,
development or commercialization of a product, that is of similar market potential at a similar
stage in its development or product life, taking into account issues of market exclusivity
(including patent coverage, regulatory and other exclusivity), safety and efficacy, product
profile, the competitiveness of alternate products in the marketplace or under development, the
launch or sales of a generic or biosimilar product, the regulatory structure involved, and the
profitability of the applicable product (including pricing and reimbursement status achieved), and
other relevant factors, including technical, commercial, legal, scientific, and/or medical factors.

“Existing Licenses” means those licenses and related agreements (for so long as they
are in effect) with respect to the Products granted by the Company or its Affiliates to third
parties (other than the Company or its Affiliates) as in effect immediately prior to the
consummation of the Merger (with such modifications thereto after the consummation of the Merger
that do not reduce the amounts of royalties, milestone payments or profit split payments
thereunder).

“Event of Default” shall have the meaning set forth in Section 8.1 of this CVR
Agreement.

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

“Exchange Act Documents” shall have the meaning set forth in Section 5.4 of this CVR
Agreement.

“FDA” means the United States Food and Drug Administration or any successor agency.

“Governmental Entity” means any domestic (federal or state), or foreign court,
commission, governmental body, regulatory or administrative agency or other political subdivision
thereof.

“Holder” means a Person in whose name a Security is registered in the Security
Register.

“Independent Accountant” shall have the meaning set forth in Section 7.6(a) of this
CVR Agreement.

“Indications” means U.S. Regulatory Approval of the Product described in clause (a) of
the definition of “Product” for use in the treatment of: (i) melanoma; (ii) ovarian cancer; (iii)
bladder cancer; and (iv) first-line metastatic breast cancer.

“Junior Obligations” has the meaning set forth in Section 10.1.

“Law” means any foreign, federal, state, local or municipal laws, rules, judgments
orders, regulations, statutes, ordinances, codes, decisions, injunctions, orders, decrees or
requirements of any Governmental Entity.

 

4

 

“Majority Holders” means, at the time of determination, Holders of at least a majority
of the Outstanding CVRs.

“Merger” shall have the meaning set forth in the Recitals of this CVR Agreement.

“Merger Agreement” shall have the meaning set forth in the Recitals of this CVR
Agreement.

“Milestone” means each of (i) Milestone #1, and (ii) Milestone #2.

“Milestone #1” means U.S. Regulatory Approval of the Product described in clause (a)
of the definition of “Product” for use in the treatment of non-small cell lung cancer (NSCLC),
which U.S. Regulatory Approval permits the Company to market such Product under a label that
includes a progression free survival claim, but only if the foregoing milestone is achieved no
later than the Milestone Target Date. For the avoidance of doubt, an “approvable letter” or
similar communication published by the FDA shall not constitute approval for purposes of the
foregoing.

“Milestone #2” means U.S. Regulatory Approval of the Product described in clause (a)
of the definition of “Product” for use in the treatment of pancreatic cancer, which U.S. Regulatory
Approval permits the Company to market such Product under a label that includes an overall survival
claim, but only if the foregoing milestone is achieved no later than the Milestone Target Date.
For the avoidance of doubt, an “approvable letter” or similar communication published by the FDA
shall not constitute approval for purposes of the foregoing.

“Milestone Payment” means, as applicable, (i) two hundred fifty million dollars
($250,000,000), with respect to the achievement of Milestone #1; and (ii) (a) four hundred million
dollars ($400,000,000), with respect to the achievement of Milestone #2 if Milestone #2 is achieved
no later than April 1, 2013, and (b) three hundred million dollars ($300,000,000), with respect to
the achievement of Milestone #2 if Milestone #2 is achieved after April 1, 2013 but no later than
the Milestone Target Date.

“Milestone Payment Date” means, with respect to each Milestone, the date that is
twenty (20) Business Days following the date of the achievement of such Milestone.

“Milestone Target Date” means the fifth anniversary of the date of this CVR Agreement.

“Net Sales” means, for each Net Sales Measuring Period, the sum of, without any
duplication: (i) the gross amounts invoiced for the Products sold by the Company, its Affiliates
or its licensees (other than licensees under Existing Licenses) to third parties (other than the
Company, its Affiliates or its licensees) during such Net Sales Measuring Period, including
wholesale distributors, less deductions from such amounts calculated in accordance with Accounting
Standards so as to arrive at “net sales” under Accounting Standards as reported by the Company, its
Affiliate or its licensee, as applicable, in such Person’s financial statements, and further
reduced by write-offs of accounts receivables or increased for collection of accounts that were
previously written off; plus (ii) (A) the amount of royalties and profit split payments received by
the Company or its Affiliates from their respective licensees under Existing Licenses
for sales (but not the supply) of Products sold by such licensees to third parties (other than
the Company or its Affiliates) during such Net Sales Measuring Period, and (B) the amount of any
milestone payments received during such Net Sales Measuring Period by the Company or its Affiliates
from their licensees under Existing Licenses with respect to the Products.

 

5

 

Any and all set-offs against gross invoice prices shall be calculated in accordance with
Accounting Standards. Sales or other commercial dispositions of a Product between the Company and
its Affiliates and its licensees shall be excluded from the computation of Net Sales; Product
provided to third parties without charge, in connection with research and development, clinical
trials, compassionate use, humanitarian and charitable donations, or indigent programs or for use
as samples shall be excluded from the computation of Net Sales; and no payments will be payable on
such sales or such other commercial dispositions, except where such an Affiliate or licensee is an
end user of the Product.

Notwithstanding the foregoing, if a Product is sold or otherwise commercially disposed of for
consideration other than cash or in a transaction that is not at arm’s length between the buyer and
the seller, then the gross amount to be included in the calculation of Net Sales shall be the
amount that would have been invoiced had the transaction been conducted at arm’s length and for
cash. Such amount that would have been invoiced shall be determined, wherever possible, by
reference to the average selling price of such Product in arm’s length transactions in the relevant
country.

Notwithstanding the foregoing, in the event a Product is sold as a Combination Product in a
particular country, Net Sales shall be calculated by multiplying the Net Sales of the Combination
Product by the fraction A/(A+B), where A is the gross invoice price of the Product if sold
separately in a country and B is the gross invoice price of the other product(s) included in the
Combination Product if sold separately in such country. If no such separate sales are made by the
Company, its Affiliates or licensees in a country, Net Sales of the Combination Product shall be
calculated in a manner determined by the Company in good faith based upon the relative value of the
active components of such Combination Product.

“Net Sales Measuring Period” means the one-year period beginning January
1st of each year during the term of this CVR Agreement and ending December
31st of each year during the term of this CVR Agreement; provided that the first Net
Sales Measuring Period will begin on January 1, 2011 and end on December 31, 2011.

“Net Sales Payment” means, with respect to any Net Sales Measuring Period, an amount
equal to (i) two and one-half percent (2.5%) of that portion of Net Sales of the Products that
exceeds one billion dollars ($1,000,000,000) but is less than or equal to two billion dollars
($2,000,000,000) for such period, plus (ii) an additional amount equal to five percent (5.0%) of
that portion of Net Sales of the Products that exceeds two billion dollars ($2,000,000,000) but is
less than or equal to three billion dollars ($3,000,000,000) for such period, plus (iii) an
additional amount equal to ten percent (10.0%) of that portion of Net Sales of the Products that
exceeds three billion dollars ($3,000,000,000) for such period; provided that no Net Sales Payments
will be due following a Net Sales Payment Termination Date.

 

6

 

“Net Sales Payment Dates” means the fifteenth (15th) day after the date the
Company is required to provide the Net Sales Statement pursuant to Section 5.4 for the Net Sales
Measuring Period in respect of which a Net Sales Payment is due.

“Net Sales Payment Termination Date” means the last day of the Net Sales Measuring
Period ending on December 31, 2025; provided that, if Net Sales of the Products for the Net Sales
Measuring Period ending on December 31, 2025 are equal to or greater than one billion dollars
($1,000,000,000), then the Net Sales Payment Termination Date shall be extended until the earlier
of (a) the last day of the first Net Sales Measuring Period subsequent to December 31, 2025 during
which Net Sales of the Products are less than one billion dollars ($1,000,000,000) and (b) December
31, 2030.

“Net Sales Statement” means, with respect to each Net Sales Measuring Period, the
written statement of the Company, certified by the Chief Financial Officer of the Company and
setting forth with reasonable detail (i)(a), for the Products for all countries in the aggregate,
(X) the total of the gross invoice price charged by the Company, its Affiliates and its licensees
(other than licensees under Existing Licenses) for sales of the Products by the Company, its
Affiliates and their respective licensees (other than licensees under Existing Licenses) to third
parties (other than the Company or its Affiliates) during the applicable period, (Y) an itemized
calculation of Net Sales for the Products showing deductions for such Net Sales Measuring Period
provided for in accordance with the definition of Net Sales, and (Z)(1) the total of all royalties
and profit split payments received by the Company and its Affiliates from their respective
licensees under Existing Licenses for sales of the Products by their respective licensees during
the applicable period, and (2) the amount of any milestone payments received during such Net Sales
Measuring Period by the Company or its Affiliates from their licensees under Existing Licenses with
respect to the Products, (b) to the extent that Net Sales for the Products for an applicable period
is determined based on Net Sales of a Combination Product for such period, the method of
determining the Net Sales of the Combination Product attributable to the Products in accordance
with the definition of Net Sales, and (c) to the extent that sales for the Products for an
applicable period is recorded in currencies other than United States dollars, the exchange rates
used for conversion of such foreign currency into United States dollars and (ii) the calculation of
the Net Sales Payment due, if any, in respect of the applicable Net Sales Measuring Period in
accordance with this CVR Agreement.

“Officer’s Certificate” when used with respect to the Company means a certificate
signed by the chairman of the Board of Directors or the president or any vice president, the
controller or assistant controller and the treasurer or assistant treasurer or the secretary or any
assistant secretary of the Company delivered to the Trustee or any other person authorized to act
on behalf of the Company.

“Opinion of Counsel” means a written opinion of counsel, who may be counsel for the
Company.

“Outstanding” when used with respect to Securities means, as of the date of
determination, all Securities theretofore authenticated and delivered under this CVR Agreement,
except: (i) Securities theretofore cancelled by the Trustee or delivered to the Trustee for
cancellation and (ii) Securities in exchange for or in lieu of which other Securities have been
authenticated and delivered pursuant to this CVR Agreement, other than any such Securities in
respect of which there shall have been presented to the Trustee proof satisfactory to it that such
Securities are held by a bona fide purchaser in whose hands the Securities are valid obligations of
the Company; provided, however, that in determining whether the Holders of the requisite
Outstanding Securities have given any request, demand, direction, consent or waiver hereunder,
Securities owned by the Company or any Affiliate of the Company, whether held as treasury
securities or otherwise, shall be disregarded and deemed not to be Outstanding.

 

7

 

“Party” shall mean the Trustee, the Company and/or Holder(s), as applicable.

“Paying Agent” means any Person authorized by the Company to pay the amount determined
pursuant to Section 3.1, if any, on any Securities on behalf of the Company.

“Payment Date” means any Net Sales Payment Date, any Milestone Payment Date, and any
such date as shall be required for any CVR Shortfall payment pursuant to the review procedure set
forth in Section 7.6.

“Person” means any individual, corporation, partnership, joint venture, association,
joint-stock company, trust, limited liability company, unincorporated organization or government or
any agency or political subdivision thereof.

“Products” means each of:

(a) the pharmaceutical product comprising the chemical compound having the chemical name of
5ß,20-Epoxy-1,2a,4,7ß,10ß,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with
(2R,3S)-N-benzoyl-3-phenylisoserine (with the structure below), known by the generic name
“paclitaxel” and bound to albumin that is the subject of the New Drug Application No. 21-660 filed
with the FDA and subject of the European Medicines Agency Marketing Authorization granted on
January 11, 2008, together with all amendments and supplements to such FDA and European Medicines
Agency approvals (identified by the Company as ABRAXANE); provided that in all cases such Product
is an injectable formulation.

 

8

 

(b) the pharmaceutical product comprising the chemical compound having the chemical name of
(2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester with 5ß-20-epoxy-1,2 ,4,7ß,10ß,13
-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, anhydrous(with the structure below) bound to
albumin that is the subject of the Investigational New Drug Application No. 73,527 filed with the
FDA together with all amendments (identified by the Company as “nab-docetaxel (ABI-008)”); provided
that in all cases such Product is an injectable formulation.

(c) the pharmaceutical product comprising the chemical compound having the chemical name of
(3S, 6R, 7E, 9R, 10R, 12R, 14S, 15E, 17E, 19E, 21S, 23S, 26R, 27R, 34aS)-9, 10, 12, 13, 14, 21, 22,
23, 24, 25, 26, 27, 32, 33, 34, 34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S, 3R,
4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6, 8, 12, 14, 20,
26-hexamethyl-23, 27-epoxy-3H-pyrido[2, 1-c][1,4] oxaazacyclohentriacontine -1, 5, 11, 28,
29 (4H,6H,31H)-pentone (with the structure below) bound to albumin that is the subject of the
Investigational New Drug Application No. 74.610 filed with the FDA together with all amendments
(identified by the Company as “nab-rapamycin (ABI-009)”); provided that in all cases such Product
is an injectable formulation.

(d) the pharmaceutical product comprising the chemical compound having the chemical name of
17-allylamino-17-demethoxygeldanamycin, 17-allylamino geldanamycin (with the structure below) bound
to albumin that is the subject of the Investigational New Drug Application No. 78,298 filed with
the FDA together with all amendments (identified by the Company as “nab-17AAG (ABI-010)”); provided
that in all cases such Product is an injectable formulation.

 

9

 

(e) the pharmaceutical product comprising the chemical compound having the chemical name of
N-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-3-[3-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-ureido]-propionamide(with the structure below) bound to albumin that is the
subject of the Investigational New Drug Application No. 103,698 filed with the FDA together with
all amendments (identified by the Company as “nab-thiocolchicine dimer (ABI-011)”); provided that
in all cases the Product is an injectable formulation.

(f) the pharmaceutical product comprising the chemical compound having the chemical name of
(αR, ßS)-ß-[[(1,1-Dimethylethoxy)carbonyl]amino]-α-(hexanoyloxy)benzenepropanoic acid
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodecal[3,4]benz[1, 2-b]oxet-9-yl ester (with the structure below) bound to albumin (identified by the Company as
“nab-novel taxane (ABI-013)”) provided that in all cases the Product is an injectable formulation.

 

10

 

(g) the pharmaceutical product comprising the chemical compound having the chemical name of
Benzenepropanoic acid,
ß-(benzoylamino)-α-hydroxy-,6,12bbis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12bdodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]-oxet-9-yl
ester,[2aR-[2aα,4ß,4aß,6ß,9α(αR*,ßS*),11α,12α,12aα, 12bα]] bound to albumin that is the subject of
the Investigational New Drug Application No. 63,082 filed with the FDA together
with all amendments (identified by the Company as “COROXANE”); provided that in all cases the
Product is an injectable formulation.

“Redemption Eligibility Date” means the date that fifty percent (50%) of the
Securities issued pursuant to the terms of the Merger Agreement either are (i) no longer
Outstanding, and/or (ii) repurchased, acquired, redeemed or retired by the Company.

“Registration Statement” shall have the meaning set forth in the Recitals of this CVR
Agreement.

“Regulatory Approval” means all approvals from the FDA or other non-U.S. regulatory
authority necessary for the commercial manufacture, marketing and sale of a product in the United
States or other jurisdiction in accordance with applicable Law.

“Representatives” shall have the meaning set forth in Section 7.13 of this CVR
Agreement.

“Responsible Officer” when used with respect to the Trustee means any officer assigned
to the Corporate Trust Office and also means, with respect to any particular corporate trust
matter, any other officer of the Trustee to whom such matter is referred because of his knowledge
of and familiarity with the particular subject.

“Securities” shall have the meaning set forth in the Preamble of this CVR Agreement.

“Securities Act” shall have the meaning set forth in the Recitals of this CVR
Agreement.

 

11

 

“Security Register” shall have the meaning set forth in Section 3.5(a) of this CVR
Agreement.

“Senior Obligations” means any existing or future obligations of the Company,
including the principal of, premium (if any), interest (including, without limitation, any interest
accruing subsequent to the filing of a petition of bankruptcy at the rate provided for in the
documentation with respect thereto, whether or not such interest is an allowed claim under
applicable Law) on, and all other amounts owing thereon, (i) with respect to borrowed money, (ii)
evidenced by notes, debentures, bonds or other similar debt instruments, (iii) with respect to the
net obligations owed under interest rate swaps or similar agreements or currency exchange
transactions, (iv) reimbursement obligations in respect of letters of credit and similar
obligations, (v) in respect of capital leases, or (vi) guarantees in respect of obligations
referred to in clauses (i) through (v) above; unless, in any case, the instrument creating or
evidencing the same or pursuant to which the same is outstanding provides that such obligations are
pari passu to or subordinate in right of payment to the Securities.

Notwithstanding the foregoing, “Senior Obligations” shall not include:

	 	(a)	 	Junior Obligations;

	 
	 	(b)	 	trade debt incurred in the ordinary course of business;

	 
	 	(c)	 	any intercompany indebtedness between the Company and any of
its Subsidiaries or Affiliates;

	 
	 	(d)	 	indebtedness of the Company that is subordinated in right of
payment to Senior Obligations;

	 
	 	(e)	 	indebtedness or other obligations of the Company that by its
terms ranks equal or junior in right of payment to the Junior Obligations;

	 
	 	(f)	 	indebtedness of the Company that, by operation of Law, is
subordinate to any general unsecured obligations of the Company; and

	 
	 	(g)	 	indebtedness evidenced by any guarantee of indebtedness ranking
equal or junior in right of payment to the Junior Obligations.

“Shortfall Interest Rate” means a rate equal to the sum of two percent (2%) plus the
prime rate of interest quoted in the Money Rates section of The Wall Street Journal (New York
Edition), or similar reputable data source, calculated daily on the basis of a three hundred
sixty-five (365) day year or, if lower, the highest rate permitted under applicable Law.

“Shortfall Report” shall have the meaning set forth in Section 7.6(b) of this CVR
Agreement.

“Sub” shall have the meaning set forth in the Recitals of this CVR Agreement.

 

12

 

“Subsidiary” means, with respect to any Person, any corporation, limited liability
company, association, partnership or other business entity of which more than fifty percent (50%)
of the total voting power of shares of Voting Securities is at the time owned or controlled,
directly or indirectly, by: (i) such Person; (ii) such Person and one or more Subsidiaries of such
Person; or (iii) one or more Subsidiaries of such Person.

“Tax” means any federal, state, local or foreign income, profits, gross receipts,
license, payroll, employment, severance, stamp, occupation, premium, windfall profits,
environmental, customs duty, capital stock, franchise, sales, social security, unemployment,
disability, use, property, withholding, excise, transfer, registration, production, value added,
alternative minimum, occupancy, estimated or any other tax of any kind whatsoever, together with
any interest, penalty or addition thereto, imposed by any Governmental Entity responsible for the
imposition of any such tax, whether disputed or not.

“Tax Return” means any return, report, declaration, claim or other statement
(including attached schedules) relating to Taxes.

“Trust Indenture Act” means the Trust Indenture Act of 1939, as amended from time to
time.

“Trustee” means the Person named as the “Trustee” in the first paragraph of this CVR
Agreement, until a successor Trustee shall have become such pursuant to the applicable provisions
of this CVR Agreement, and thereafter “Trustee” shall mean such successor Trustee.

“Vice President” when used with respect to the Company or the Trustee, means any vice
president, whether or not designated by a number or a word or words added before or after the title
of “vice president.”

“Voting Securities” means securities or other interests having voting power, or the
right, to elect or appoint a majority of the directors, or any Persons performing similar
functions, irrespective of whether or not stock or other interests of any other class or classes
shall have or might have voting power or any right by reason of the happening of any contingency.

Section 1.2 Compliance and Opinions.

(a) Upon any application or request by the Company to the Trustee to take any action under any
provision of this CVR Agreement, the Company shall furnish to the Trustee an Officers’ Certificate
stating that, in the opinion of the signor, all conditions precedent, if any, provided for in this
CVR Agreement relating to the proposed action have been complied with and an Opinion of Counsel
stating, subject to customary exceptions, that in the opinion of such counsel all such conditions
precedent, if any, have been complied with, except that, in the case of any such application or
request as to which the furnishing of such documents is specifically required by any provision of
this CVR Agreement relating to such particular application or request, no additional certificate or
opinion need be furnished.

 

13

 

(b) Every certificate or opinion with respect to compliance with a condition or covenant
provided for in this CVR Agreement shall include: (i) a statement that each individual signing such
certificate or opinion has read such covenant or condition and the definitions herein relating
thereto; (ii) a brief statement as to the nature and scope of the examination or investigation upon
which the statements or opinions contained in such certificate or opinion are based; (iii) a
statement that, in the opinion of each such individual, he or she has made such examination or
investigation as is necessary to enable him to express an informed opinion as to whether or not
such covenant or condition has been complied with; and (iv) a statement as to whether, in the
opinion of each such individual, such condition or covenant has been complied with.

Section 1.3 Form of Documents Delivered to Trustee.

(a) In any case where several matters are required to be certified by, or covered by an
opinion of, any specified Person, it is not necessary that all such matters be certified by, or
covered by the opinion of, only one such Person, or that they be so certified or covered by only
one document, but one such Person may certify or give an opinion with respect to some matters and
one or more other such Persons as to other matters, and any such Person may certify or give an
opinion as to such matters in one or several documents.

(b) Any certificate or opinion of an officer of the Company may be based, insofar as it
relates to legal matters, upon a certificate or opinion of, or representations by, counsel. Any
such certificate or Opinion of Counsel may be based, insofar as it relates to factual
matters, upon a certificate or opinion of, or representations by, an officer or officers of
the Company stating that the information with respect to such factual matters is in the possession
of the Company.

(c) Any certificate, statement or opinion of an officer of the Company or of counsel may be
based, insofar as it relates to accounting matters, upon a certificate or opinion of or
representations by an accountant or firm of accountants in the employ of the Company. Any
certificate or opinion of any independent firm of public accountants filed with the Trustee shall
contain a statement that such firm is independent.

(d) Where any Person is required to make, give or execute two or more applications, requests,
consents, certificates, statements, opinions or other instruments under this CVR Agreement, they
may, but need not, be consolidated and form one instrument.

Section 1.4 Acts of Holders.

(a) Any request, demand, authorization, direction, notice, consent, waiver or other action
provided by this CVR Agreement to be given or taken by Holders may be embodied in and evidenced by
one or more instruments of substantially similar tenor signed by such Holders in person or by an
agent duly appointed in writing; and, except as herein otherwise expressly provided, such action
shall become effective when such instrument or instruments are delivered to the Trustee and, where
it is hereby expressly required, to the Company. Such instrument or instruments (and the action
embodied therein and evidenced thereby) are herein sometimes referred to as the “Act” of the
Holders signing such instrument or instruments. Proof of execution of any such instrument or of a
writing appointing any such agent shall be sufficient for any purpose of this CVR Agreement and
(subject to Section 4.1) conclusive in favor of the Trustee and the Company, if made in the manner
provided in

 

14

 

this Section. The Company may set a record date for purposes of determining the
identity of Holders entitled to vote or consent to any action by vote or consent authorized or
permitted under this CVR Agreement. If not previously set by the Company, (i) the record date for
determining the Holders entitled to vote at a meeting of the Holders shall be the date preceding
the date notice of such meeting is mailed to the Holders, or if notice is not given, on the day
next preceding the day such meeting is held, and (ii) the record date for determining the Holders
entitled to consent to any action in writing without a meeting shall be the first date on which a
signed written consent setting forth the action taken or proposed to be taken is delivered to the
Company. If a record date is fixed, those Persons who were Holders of Securities at such record
date (or their duly designated proxies), and only those Persons, shall be entitled to take such
action by vote or consent or, except with respect to clause (d) below, to revoke any vote or
consent previously given, whether or not such Persons continue to be Holders after such record
date. No such vote or consent shall be valid or effective for more than one hundred twenty (120)
days after such record date.

(b) The fact and date of the execution by any Person of any such instrument or writing may be
proved in any reasonable manner which the Trustee deems sufficient.

(c) The ownership of Securities shall be proved by the Security Register. Neither the Company
nor the Trustee nor any Agent of the Company or the Trustee shall be affected by any notice to the
contrary.

(d) At any time prior to (but not after) the evidencing to the Trustee, as provided in this
Section 1.4, of the taking of any action by the Holders of the Securities specified in this CVR
Agreement in connection with such action, any Holder of a Security the serial number of which is
shown by the evidence to be included among the serial numbers of the Securities the Holders of
which have consented to such action may, by filing written notice at the Corporate Trust Office and
upon proof of holding as provided in this Section 1.4, revoke such action so far as concerns such
Security. Any request, demand, authorization, direction, notice, consent, waiver or other action
by the Holder of any Security shall bind every future Holder of the same Security or the Holder of
every Security issued upon the registration of transfer thereof or in exchange therefor or in lieu
thereof, in respect of anything done, suffered or omitted to be done by the Trustee, any Paying
Agent or the Company in reliance thereon, whether or not notation of such action is made upon such
Security.

Section 1.5 Notices, etc., to Trustee and Company. Any request, demand,
authorization, direction, notice, consent, waiver or Act of Holders or other document provided or
permitted by this CVR Agreement to be made upon, given or furnished to, or filed with:

(a) the Trustee by any Holder or by the Company shall be sufficient for every purpose
hereunder if made, given, furnished or filed, in writing, to or with the Trustee at its Corporate
Trust Office; or

(b) the Company by the Trustee or by any Holder shall be sufficient for every purpose
hereunder if in writing and mailed, first-class postage prepaid, to the Company addressed to it at
Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901, Legal Department, Attention:
Senior Vice President and Chief Counsel, or at any other address previously furnished in writing to
the Trustee by the Company.

 

15

 

Section 1.6 Notice to Holders; Waiver.

(a) Where this CVR Agreement provides for notice to Holders of any event, such notice shall be
sufficiently given (unless otherwise herein expressly provided) if in writing and mailed,
first-class postage prepaid, to each Holder affected by such event, at his address as it appears in
the Security Register, not later than the latest date, and not earlier than the earliest date,
prescribed for the giving of such notice. In any case where notice to Holders is given by mail,
neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular
Holder shall affect the sufficiency of such notice with respect to other Holders. Where this CVR
Agreement provides for notice in any manner, such notice may be waived in writing by the Person
entitled to receive such notice, either before or after the event, and such waiver shall be the
equivalent of such notice. Waivers of notice by Holders shall be filed with the Trustee, but such
filing shall not be a condition precedent to the validity of any action taken in reliance upon such
waiver.

(b) In case by reason of the suspension of regular mail service or by reason of any other
cause, it shall be impracticable to mail notice of any event as required by any provision of this
CVR Agreement, then any method of giving such notice as shall be satisfactory to the Trustee shall
be deemed to be a sufficient giving of such notice.

Section 1.7 Conflict with Trust Indenture Act. If any provision hereof limits,
qualifies or conflicts with another provision hereof which is required to be included in this CVR
Agreement by any of the provisions of the Trust Indenture Act, such required provision shall
control.

Section 1.8 Effect of Headings and Table of Contents. The Article and Section
headings herein and the Table of Contents are for convenience only and shall not affect the
construction hereof.

Section 1.9 Benefits of Agreement. Nothing in this CVR Agreement or in the
Securities, express or implied, shall give to any Person (other than the Parties hereto and their
successors hereunder, any Paying Agent and the Holders) any benefit or any legal or equitable
right, remedy or claim under this CVR Agreement or under any covenant or provision herein
contained, all such covenants and provisions being for sole benefit of the Parties hereto and their
successors, any Paying Agent and of the Holders.

Section 1.10 Governing Law. THIS CVR AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK INCLUDING, WITHOUT LIMITATION, SECTIONS 5-1401
AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW WITHOUT REGARD TO THE CONFLICT OF LAWS
PRINCIPLES THEREOF. EACH OF THE COMPANY, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE
OF THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE
COURT SITTING IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK OR ANY FEDERAL COURT SITTING IN
THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN RESPECT OF ANY SUIT, ACTION OR PROCEEDING
ARISING OUT OF OR RELATING TO THIS CVR AGREEMENT AND

 

16

 

THE SECURITIES, AND IRREVOCABLY ACCEPTS FOR
ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE AFORESAID
COURTS. EACH OF THE COMPANY AND THE TRUSTEE AGREES THAT PROCESS MAY BE SERVED UPON THEM IN ANY
MANNER AUTHORIZED BY THE LAWS OF THE STATE OF NEW YORK FOR SUCH PERSONS AND IRREVOCABLY WAIVES, TO
THE FULLEST EXTENT IT MAY EFFECTIVELY DO SO UNDER APPLICABLE LAW, ANY OBJECTION IT MAY NOW OR
HEREAFTER HAVE TO SUCH SERVICE OF PROCESS, THE LAYING OF THE VENUE OF ANY SUCH SUIT, ACTION OR
PROCEEDING BROUGHT IN ANY SUCH COURT AND ANY CLAIM THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT
IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

Section 1.11 Legal Holidays. In the event that a Payment Date shall not be a Business
Day, then (notwithstanding any provision of this CVR Agreement or the Securities to the contrary)
payment on the Securities need not be made on such date, but may be made, without the accrual of
any interest thereon, on the next succeeding Business Day with the same force and effect as if made
on such Payment Date.

Section 1.12 Separability Clause. In case any provision in this CVR Agreement or in
the CVRs shall be invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.

Section 1.13 No Recourse Against Others. A director, officer or employee, as such, of
the Company or the Trustee shall not have any liability for any obligations of the Company or the
Trustee under the Securities or this CVR Agreement or for any claim based on, in respect of or by
reason of such obligations or their creation. By accepting a Security each Holder waives and
releases all such liability. The waiver and release are part of the consideration for the issue of
the Securities.

Section 1.14 Counterparts. This CVR Agreement shall be signed in any number of
counterparts with the same effect as if the signatures to each counterpart were upon a single
instrument, and all such counterparts together shall be deemed an original of this CVR Agreement.

Section 1.15 Acceptance of Trust. [•], the Trustee named herein, hereby accepts the
trusts in this CVR Agreement declared and provided, upon the terms and conditions set forth herein.

ARTICLE 2

SECURITY FORMS

Section 2.1 Forms Generally.

(a) The Securities and the Trustee’s certificate of authentication shall be in substantially
the forms set forth in Annex A, attached hereto and incorporated herein by this reference, with
such appropriate insertions, omissions, substitutions and other variations as are required or
permitted by this CVR Agreement and may have such letters, numbers or other marks of identification
and such legends or endorsements placed thereon as may be required to comply with the rules of any
securities exchange or as may be required by Law or any rule or regulation pursuant thereto, all as
may be determined by the officers executing such Securities, as evidenced by their execution of the
Securities. Any portion of the text of any Security may be set forth on the reverse thereof, with
an appropriate reference thereto on the face of the Security.

 

17

 

(b) The definitive Securities shall be typewritten, printed, lithographed or engraved on steel
engraved borders or produced by any combination of these methods or may be produced in any other
manner permitted by the rules of any securities exchange on which the Securities may be listed, all
as determined by the officers executing such Securities, as evidenced by their execution of such
Securities.

ARTICLE 3

THE SECURITIES

Section 3.1 Title and Terms.

(a) The aggregate number of CVRs in respect of which CVR Certificates may be authenticated and
delivered under this CVR Agreement is limited to a number equal to [•]1, except for Securities
authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of,
other Securities pursuant to Section 3.4, 3.5, 3.6 or 6.6. From and after the Effective Time, the
Company shall not be permitted to issue any CVRs that have the right to receive any portion of the
Milestone Payments or the Net Sales Payments, except as provided and in accordance with the terms
and conditions of the Merger Agreement.

(b) The Securities shall be known and designated as the “Series A Contingent Value Rights” of
the Company.

(c) On each Net Sales Payment Date, the Company shall pay to the Trustee, by wire transfer to
the account designated by the Trustee, the Net Sales Payment due, if any, in respect of the Net
Sales Measuring Period ended immediately preceding such Net Sales Payment Date, and the Trustee
shall pay the Holders of the Securities as of such Net Sales Payment Date, a pro rata portion of
such Net Sales Payment based on the number of CVRs held by each Holder as of such date.
Notwithstanding the foregoing, the Company’s obligations to pay any Net Sales Payment shall
terminate in its entirety on the Net Sales Payment Termination Date.

(d) On each Milestone Payment Date, the Company shall pay to the Trustee, by wire transfer to
the account designated by the Trustee, the applicable Milestone Payment, and the Trustee shall pay
to the Holders of the Securities as of such Milestone Payment Date, a pro rata portion of such
Milestone Payment based on the number of CVRs held by each Holder as of such date. Notwithstanding
the foregoing, the Company’s obligations to pay any Milestone Payment shall terminate in its
entirety if the corresponding Milestone for such Milestone Payment has not been achieved by the
Milestone Target Date.

 

	 	 	 
	 	 	1 Insert total, as of the closing of the Merger, of all CVRs to be
issued pursuant to the Merger Agreement.

 

18

 

(e) The Holders of the CVR Certificates, by acceptance thereof, agree that no joint venture,
partnership or other fiduciary relationship is created hereby or by the Securities.

(f) Other than in the case of interest on amounts due and payable after the occurrence of an
Event of Default or with respect to any CVR Shortfall, no interest or dividends shall accrue on any
amounts payable in respect of the CVRs.

(g) Except to the extent any portion of any CVR Payment is required to be treated as imputed
interest pursuant to applicable Law, the Parties hereto agree to treat the CVRs and all CVR
Payments for all Tax purposes as additional consideration for the shares of Common Stock, the
Options, the SARs and the RSUs pursuant to the Merger Agreement, and none of the Parties hereto
will take any position to the contrary on any Tax Return or for other
Tax purposes except as required by applicable Law. The Company shall report imputed interest
on the CVRs pursuant to Section 483 of the Code.

(h) The CVRs and any interest thereon may be sold, assigned, pledged encumbered or in any
manner transferred or disposed of, in whole or in part, only in compliance with applicable United
States federal and state securities Laws and, to the extent applicable, in accordance with Section
3.5 hereof.

(i) The Holder of any CVR or CVR Certificate is not, and shall not, by virtue thereof, be
entitled to any rights of a holder of any Voting Securities or other equity security or other
ownership interest of the Company or in any constituent company to the Merger, either at Law or in
equity, and the rights of the Holders are limited to those contractual rights expressed in this CVR
Agreement.

(j) Except as provided in this CVR Agreement (including, without limitation, Section 7.6),
none of the Company or any of its Affiliates shall have any right to set-off any amounts owed or
claimed to be owed by any Holder to any of them against such Holder’s Securities or any CVR Payment
or other amount payable to such Holder in respect of such Securities.

(k) In the event that all of the CVR Certificates not previously cancelled shall have become
due and payable pursuant to the terms hereof, all disputes with respect to amounts payable to the
Holders brought pursuant to the terms and conditions of this CVR Agreement have been resolved, and
the Company has paid or caused to be paid or deposited with the Trustee all amounts payable to the
Holders under this CVR Agreement (including any amounts determined in accordance with Section 7.6
herein), then this CVR Agreement shall cease to be of further effect and shall be deemed satisfied
and discharged. Notwithstanding the satisfaction and discharge of this CVR Agreement, the
obligations of the Company under Section 4.7(c) shall survive.

 

19

 

Section 3.2 Registrable Form. The Securities shall be issuable only in registered
form.

Section 3.3 Execution, Authentication, Delivery and Dating.

(a) The Securities shall be executed on behalf of the Company by its chairman of the Board of
Directors or its president or any vice president or its treasurer, but need not be attested. The
signature of any of these officers on the Securities may be manual or facsimile.

(b) Securities bearing the manual or facsimile signatures of individuals who were, at the time
of execution, the proper officers of the Company shall bind the Company, notwithstanding that such
individuals or any of them have ceased to hold such offices prior to the authentication and
delivery of such Securities or did not hold such offices at the date of such Securities.

(c) At any time and from time to time after the execution and delivery of this CVR Agreement,
the Company may deliver Securities executed by the Company to the Trustee for authentication,
together with a Company Order for the authentication and delivery of such
Securities; and the Trustee, in accordance with such Company Order, shall authenticate and
deliver such Securities as provided in this CVR Agreement and not otherwise.

(d) Each Security shall be dated the date of its authentication.

(e) No Security shall be entitled to any benefit under this CVR Agreement or be valid or
obligatory for any purpose unless there appears on such Security a certificate of authentication
substantially in the form provided for herein duly executed by the Trustee, by manual or facsimile
signature of an authorized officer, and such certificate upon any Security shall be conclusive
evidence, and the only evidence, that such Security has been duly authenticated and delivered
hereunder and that the Holder is entitled to the benefits of this CVR Agreement.

Section 3.4 Temporary Securities.

(a) Pending the preparation of definitive Securities, the Company may execute, and upon
Company Order, the Trustee shall authenticate and deliver, temporary Securities which are printed,
lithographed, typewritten, mimeographed or otherwise produced, substantially of the tenor of the
definitive Securities in lieu of which they are issued and with such appropriate insertions,
omissions, substitutions and other variations as the officers executing such Securities may
determine with the concurrence of the Trustee. Temporary Securities may contain such reference to
any provisions of this CVR Agreement as may be appropriate. Every temporary Security shall be
executed by the Company and be authenticated by the Trustee upon the same conditions and in
substantially the same manner, and with like effect, as the definitive Securities.

(b) If temporary Securities are issued, the Company will cause definitive Securities to be
prepared without unreasonable delay. After the preparation of definitive Securities, the temporary
Securities shall be exchangeable for definitive Securities upon surrender of the temporary
Securities at the office or agency of the Company designated for such purpose pursuant to Section
7.2, without charge to the Holder. Upon surrender for cancellation of any one or more temporary
Securities, the Company shall execute and the Trustee shall authenticate and deliver in exchange
therefor a like amount of definitive Securities. Until so exchanged, the Temporary Securities
shall in all respects be entitled to the same benefits under this CVR Agreement as definitive
Securities.

 

20

 

Section 3.5 Registration, Registration of Transfer and Exchange.

(a) The Company shall cause to be kept at the office of the Trustee a register (the register
maintained in such office and in any other office or agency designated pursuant to Section 7.2
being herein sometimes referred to as the “Security Register”) in which, subject to such
reasonable regulations as it may prescribe, the Company shall provide for the registration of
Securities and of transfers of Securities. The Trustee is hereby initially appointed “Security
Registrar” for the purpose of registering Securities and transfers of Securities as herein
provided.

(b) Upon surrender for registration of transfer of any Security at the office or agency of the
Company designated pursuant to Section 7.2, the Company shall execute, and the Trustee shall
authenticate and deliver, in the name of the designated transferee or transferees, one
or more new CVR Certificates representing the same aggregate number of CVRs represented by the
CVR Certificate so surrendered that are to be transferred and the Company shall execute and the
Trustee shall authenticate and deliver, in the name of the transferor, one or more new CVR
Certificates representing the aggregate number of CVRs represented by such CVR Certificate that are
not to be transferred.

(c) At the option of the Holder, CVR Certificates may be exchanged for other CVR Certificates
that represent in the aggregate the same number of CVRs as the CVR Certificates surrendered at such
office or agency. Whenever any CVR Certificates are so surrendered for exchange, the Company shall
execute, and the Trustee shall authenticate and deliver, the CVR Certificates which the Holder
making the exchange is entitled to receive.

(d) All Securities issued upon any registration of transfer or exchange of Securities shall be
the valid obligations of the Company, evidencing the same rights, and entitled to the same benefits
under this CVR Agreement, as the Securities surrendered upon such registration of transfer or
exchange.

(e) Every Security presented or surrendered for registration of transfer or for exchange shall
(if so required by the Company or the Security Registrar) be duly endorsed, or be accompanied by a
written instrument of transfer in form satisfactory to the Company and the Security Registrar, duly
executed by the Holder thereof or his attorney duly authorized in writing.

(f) No service charge shall be made for any registration of transfer or exchange of
Securities, but the Company may require payment of a sum sufficient to cover any tax or other
governmental charge that may be imposed in connection with any registration of transfer or exchange
of Securities, other than exchanges pursuant to Section 3.4 or 6.6 not involving any transfer.

 

21

 

Section 3.6 Mutilated, Destroyed, Lost and Stolen Securities.

(a) If (i) any mutilated Security is surrendered to the Trustee, or (ii) the Company and the
Trustee receive evidence to their satisfaction of the destruction, loss or theft of any Security,
and there is delivered to the Company and the Trustee such security or indemnity as may be required
by them to save each of them harmless, then, in the absence of notice to the Company or the Trustee
that such Security has been acquired by a bona fide purchaser, the Company shall execute and, upon
delivery of a Company Order, the Trustee shall authenticate and deliver, in exchange for any such
mutilated Security or in lieu of any such destroyed, lost or stolen Security, a new CVR Certificate
of like tenor and amount of CVRs, bearing a number not contemporaneously outstanding.

(b) In case any such mutilated, destroyed, lost or stolen Security has become or is to become
finally due and payable within fifteen (15) days, the Company in its discretion may, instead of
issuing a new CVR Certificate, pay to the Holder of such Security on the applicable Payment Date,
as the case may be, all amounts due and payable with respect thereto.

(c) Every new Security issued pursuant to this Section 3.6 in lieu of any destroyed, lost or
stolen Security shall constitute an original additional contractual obligation of
the Company, whether or not the destroyed, lost or stolen Security shall be at any time
enforceable by anyone, and shall be entitled to all benefits of this CVR Agreement equally and
proportionately with any and all other Securities duly issued hereunder.

(d) The provisions of this Section are exclusive and shall preclude (to the extent lawful) all
other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost
or stolen Securities.

Section 3.7 Payments with respect to CVR Certificates. Payment of any amounts
pursuant to the CVRs shall be made in such coin or currency of the United States of America as at
the time is legal tender for the payment of public and private debts. The Company may, at its
option, pay such amounts by wire transfer or check payable in such money.

Section 3.8 Persons Deemed Owners. Prior to the time of due presentment for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may
treat the Person in whose name any Security is registered as the owner of such Security for the
purpose of receiving payment on such Security and for all other purposes whatsoever, whether or not
such Security be overdue, and neither the Company, the Trustee nor any agent of the Company or the
Trustee shall be affected by notice to the contrary.

Section 3.9 Cancellation. All Securities surrendered for payment, registration of
transfer or exchange shall, if surrendered to any Person other than the Trustee, be delivered to
the Trustee and shall be promptly canceled by it. The Company may at any time deliver to the
Trustee for cancellation any Securities previously authenticated and delivered hereunder which the
Company may have acquired in any manner whatsoever, and all Securities so delivered shall be
promptly canceled by the Trustee. No Securities shall be authenticated in lieu of or in exchange
for any Securities canceled as provided in this Section, except as expressly permitted by this CVR
Agreement. All cancelled Securities held by the Trustee shall be destroyed and a certificate of
destruction shall be issued by the Trustee to the Company, unless otherwise directed by a Company
Order.

 

22

 

ARTICLE 4

THE TRUSTEE

Section 4.1 Certain Duties and Responsibilities. (a) With respect to the Holders, the
Trustee, prior to the occurrence of an Event of Default (as defined in Section 8.1) with respect to
the Securities and after the curing or waiving of all Events of Default which may have occurred,
undertakes to perform such duties and only such duties as are specifically set forth in this CVR
Agreement and no implied covenants shall be read into this CVR Agreement against the Trustee. In
case an Event of Default with respect to the Securities has occurred (which has not been cured or
waived), the Trustee shall exercise such of the rights and powers vested in it by this CVR
Agreement, and use the same degree of care and skill in their exercise, as a prudent person would
exercise or use under the circumstances in the conduct of his own affairs.

(b) In the absence of bad faith on its part, prior to the occurrence of an Event of Default
and after the curing or waiving of all such Events of Default which may have
occurred, the Trustee may conclusively rely, as to the truth of the statements and the
correctness of the opinions expressed therein, upon certificates or opinions furnished to the
Trustee which conform to the requirements of this CVR Agreement; but in the case of any such
certificates or opinions which by any provision hereof are specifically required to be furnished to
the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they
conform to the requirements of this CVR Agreement.

(c) No provision of this CVR Agreement shall be construed to relieve the Trustee from
liability for its own negligent action, its own negligent failure to act, or its own willful
misconduct, except that (i) this Subsection (c) shall not be construed to limit the effect of
Subsections (a) and (b) of this Section; (ii) the Trustee shall not be liable for any error of
judgment made in good faith by a Responsible Officer, unless it shall be proved that the Trustee
was negligent in ascertaining the pertinent facts; and (iii) the Trustee shall not be liable with
respect to any action taken or omitted to be taken by it in good faith in accordance with the
direction of the Holders pursuant to Section 8.9 relating to the time, method and place of
conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power
conferred upon the Trustee, under this CVR Agreement.

(d) Whether or not therein expressly so provided, every provision of this CVR Agreement
relating to the conduct or affecting the liability of or affording protection to the Trustee shall
be subject to the provisions of this Section.

Section 4.2 Certain Rights of Trustee. Subject to the provisions of Section 4.1,
including without limitation, the duty of care that the Trustee is required to exercise upon the
occurrence of an Event of Default:

(a) the Trustee may rely and shall be protected in acting or refraining from acting upon any
resolution, certificate, statement, instrument, opinion, report, notice, request, direction,
consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document
believed by it to be genuine and to have been signed or presented by the proper party or parties
and the Trustee need not investigate any fact or matter stated in the document;

 

23

 

(b) any request or direction or order of the Company mentioned herein shall be sufficiently
evidenced by a Company Request or Company Order and any resolution of the Board of Directors may be
sufficiently evidenced by a Board Resolution and the Trustee shall not be liable for any action it
takes or omits to take in good faith reliance thereon;

(c) whenever in the administration of this CVR Agreement the Trustee shall deem it desirable
that a matter be proved or established prior to taking, suffering or omitting any action hereunder,
the Trustee (unless other evidence be herein specifically prescribed) may, in the absence of bad
faith on its part, rely upon an Officers’ Certificate and the Trustee shall not be liable for any
action it takes or omits to take in good faith reliance thereon or an Opinion of Counsel;

(d) the Trustee may consult with counsel and the written advice of such counsel or any Opinion
of Counsel shall be full and complete authorization and protection in
respect of any action taken, suffered or omitted by it hereunder in good faith and in
accordance with such advice or Opinion of Counsel;

(e) the Trustee shall be under no obligation to exercise any of the rights or powers vested in
it by this CVR Agreement at the request or direction of any of the Holders pursuant to this CVR
Agreement, unless such Holders shall have offered to the Trustee reasonable security or indemnity
against the costs, expenses and liabilities which might be incurred by it in compliance with such
request or direction;

(f) the Trustee shall not be bound to make any investigation into the facts or matters stated
in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent,
order, approval, appraisal, bond, debenture, note, coupon, security, or other paper or document,
but the Trustee in its discretion may make such further inquiry or investigation into such facts or
matters as it may see fit, and if the Trustee shall determine to make such further inquiry or
investigation, it shall be entitled to examine the books, records and premises of the Company,
personally or by agent or attorney;

(g) the Trustee may execute any of the trusts or powers hereunder or perform any duties
hereunder either directly or by or through agents or attorneys and the Trustee shall not be
responsible for any misconduct or negligence on the part of any agent or attorney appointed with
due care by it hereunder; and

(h) the Trustee shall not be liable for any action taken, suffered or omitted to be taken by
it in good faith and believed by it to be authorized or within the discretion or rights or powers
conferred upon it by this CVR Agreement.

Section 4.3 Notice of Default. If a default occurs hereunder with respect to the
Securities, the Trustee shall give the Holders notice of any such default actually known to it as
and to the extent applicable and provided by the Trust Indenture Act; provided, however, that in
the case of any default of the character specified in Section 8.1(b) with respect to the
Securities, no notice to Holders shall be given until at least thirty (30) days after the
occurrence thereof. For the purpose of this Section 4.3, the term “default” means any event that
is, or after notice or lapse of time or both would become, an Event of Default with respect to the
Securities.

 

24

 

Section 4.4 Not Responsible for Recitals or Issuance of Securities. The Trustee shall
not be accountable for the Company’s use of the Securities or the proceeds from the Securities.
The recitals contained herein and in the Securities, except the Trustee’s certificates of
authentication, shall be taken as the statements of the Company, and the Trustee assumes no
responsibility for their correctness. The Trustee makes no representations as to the validity or
sufficiency of this CVR Agreement or of the Securities.

Section 4.5 May Hold Securities. The Trustee, any Paying Agent, Security Registrar or
any other agent of the Company, in its individual or any other capacity, may become the owner or
pledgee of Securities, and, subject to Sections 4.8 and 4.13, may otherwise deal with the Company
with the same rights it would have if it were not Trustee, Paying Agent, Security Registrar or such
other agent.

Section 4.6 Money Held in Trust. Money held by the Trustee in trust hereunder need
not be segregated from other funds except to the extent required by Law. The Trustee shall be
under no liability for interest on any money received by it hereunder.

Section 4.7 Compensation and Reimbursement. The Company agrees:

(a) to pay to the Trustee from time to time reasonable compensation for all services rendered
by it hereunder in such amount as the Company and the Trustee shall agree from time to time (which
compensation shall not be limited by any provision of Law in regard to the compensation of a
trustee of an express trust);

(b) except as otherwise expressly provided herein, to reimburse the Trustee upon its request
for all reasonable expenses, disbursements and advances incurred or made by the Trustee in
accordance with any provision of this CVR Agreement (including the reasonable compensation and the
reasonable expenses and disbursements of its agents and counsel), except any such expense,
disbursement or advance as may be attributable to the Trustee’s negligence or willful misconduct;
and

(c) to indemnify the Trustee and each of its agents, officers, directors and employees (each
an “indemnitee”) for, and to hold it harmless against, any loss, liability or expense (including
attorneys fees and expenses) incurred without negligence or bad faith on its part, arising out of
or in connection with the acceptance or administration of this trust and the performance of its
duties hereunder, including the reasonable costs and expenses of defending itself against any claim
or liability in connection with the exercise or performance of any of its powers or duties
hereunder. The Company’s payment obligations pursuant to this Section shall survive the
termination of this CVR Agreement. When the Trustee incurs expenses after the occurrence of an
Event of Default specified in Section 8.1(c) or 8.1(d) with respect to the Company, the expenses
are intended to constitute expenses of administration under bankruptcy Laws.

 

25

 

Section 4.8 Disqualification; Conflicting Interests.

(a) If applicable, to the extent that the Trustee or the Company determines that the Trustee
has a conflicting interest within the meaning of the Trust Indenture Act, the Trustee shall, within
ninety (90) days after ascertaining that it has such conflicting interest, either eliminate such
conflicting interest or resign to the extent and in the manner provided by, and subject to the
provisions of, the Trust Indenture Act and this CVR Agreement. The Company shall take prompt steps
to have a successor appointed in the manner provided in this CVR Agreement.

(b) In the event the Trustee shall fail to comply with the foregoing subsection 4.8(a), the
Trustee shall, within ten (10) days of the expiration of such ninety (90) day period, transmit a
notice of such failure to the Holders in the manner and to the extent provided in the Trust
Indenture Act and this CVR Agreement.

(c) If the Trustee fails to comply with Section 4.8(a) after written request therefore by the
Company or any Holder, any Holder of any Security who has been a bona fide Holder for at least six
(6) months may on behalf of himself and all others similarly situated,
petition any court of competent jurisdiction for the removal of such Trustee and the
appointment of a successor Trustee.

Section 4.9 Corporate Trustee Required; Eligibility. There shall at all times be a
Trustee hereunder which satisfies the applicable requirements of Sections 310(a)(1) and (5) of the
Trust Indenture Act and has a combined capital and surplus of at least one hundred fifty million
dollars ($150,000,000). If such corporation publishes reports of condition at least annually,
pursuant to Law or to the requirements of a supervising or examining authority, then for the
purposes of this Section 4.9, the combined capital and surplus of such corporation shall be deemed
to be its combined capital and surplus as set forth in its most recent report of condition so
published. If at any time the Trustee shall cease to be eligible in accordance with the provisions
of this Section, it shall resign immediately in the manner and with the effect hereinafter
specified in this Article.

Section 4.10 Resignation and Removal; Appointment of Successor.

(a) No resignation or removal of the Trustee and no appointment of a successor Trustee
pursuant to this Article shall become effective until the acceptance of appointment by the
successor Trustee under Section 4.11.

(b) The Trustee, or any trustee or trustees hereafter appointed, may resign at any time by
giving written notice thereof to the Company. If an instrument of acceptance by a successor
Trustee shall not have been delivered to the Trustee within thirty (30) days after the giving of
such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction
for the appointment of a successor Trustee.

(c) The Trustee may be removed at any time by an act of the Majority Holders, delivered to the
Trustee and to the Company.

(d) If at any time:

(1) the Trustee shall fail to comply with Section 4.8 after written request therefor by
the Company or by any Holder who has been a bona fide Holder of a Security for at least six
months, or

 

26

 

(2) the Trustee shall cease to be eligible under Section 4.9 and shall fail to resign
after written request therefor by the Company or by any such Holder, or

(3) the Trustee shall become incapable of acting or shall be adjudged a bankrupt or
insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public
officer shall take charge or control of the Trustee or of its property or affairs for the
purpose of rehabilitation, conservation or liquidation, then, in any case, (i) the Company,
by a Board Resolution, may remove the Trustee, or (ii) the Holder of any Security who has
been a bona fide Holder of a Security for at least six months may, on behalf of himself and
all others similarly situated, petition any court of competent jurisdiction for the removal
of the Trustee and the appointment of a successor Trustee.

(e) If the Trustee shall resign, be removed or become incapable of acting, or if a vacancy
shall occur in the office of Trustee for any cause, the Company, by a Board Resolution, shall
promptly appoint a successor Trustee. If, within one year after any removal by Holders of a
majority of the Outstanding Securities, a successor Trustee shall be appointed by act of the
Holders of a majority of the Outstanding Securities delivered to the Company and the retiring
Trustee the successor Trustee so appointed shall, forthwith upon its acceptance of such appointment
in accordance with Section 4.11, become the successor Trustee and supersede the successor Trustee
appointed by the Company. If no successor Trustee shall have been so appointed by the Company or
the Holders of the Securities and accepted appointment within sixty (60) days after the retiring
Trustee tenders its resignation or is removed, the retiring Trustee may, or, the Holder of any
Security who has been a bona fide Holder for at least six (6) months may on behalf of himself and
all others similarly situated, petition any court of competent jurisdiction for the appointment of
a successor Trustee.

(f) The Company shall give notice of each resignation and each removal of the Trustee and each
appointment of a successor Trustee by mailing written notice of such event by first-class mail,
postage prepaid, to the Holders of Securities as their names and addresses appear in the Security
Register. Each notice shall include the name of the successor Trustee and the address of its
Corporate Trust Office. If the Company fails to send such notice within ten (10) days after
acceptance of appointment by a successor Trustee, it shall not be a default hereunder but the
successor Trustee shall cause the notice to be mailed at the expense of the Company.

Section 4.11 Acceptance of Appointment of Successor.

(a) Every successor Trustee appointed hereunder shall execute, acknowledge and deliver to the
Company and to the retiring Trustee an instrument accepting such appointment, and thereupon the
resignation or removal of the retiring Trustee shall become effective and such successor Trustee,
without any further act, deed or conveyance, shall become vested with all the rights, powers,
trusts and duties of the retiring Trustee; but, upon request of the Company or the successor
Trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an
instrument transferring to such successor Trustee all the rights, powers and trusts of the retiring
Trustee, and shall duly assign, transfer and deliver to such successor Trustee all property and
money held by such retiring Trustee hereunder. Upon request of any such successor Trustee, the
Company shall execute any and all instruments for more fully and certainly vesting in and
confirming to such successor Trustee all such rights, powers and trusts.

 

27

 

(b) No successor Trustee shall accept its appointment unless at the time of such acceptance
such successor Trustee shall be qualified and eligible under this Article.

Section 4.12 Merger, Conversion, Consolidation or Succession to Business. Any
corporation into which the Trustee may be merged or converted or with which it may be consolidated,
or any corporation resulting from any merger, conversion or consolidation to which the Trustee
shall be a party, or any corporation succeeding to all or substantially all of the corporate trust
business of the Trustee, by sale or otherwise shall be the successor of the Trustee hereunder,
provided such corporation shall be otherwise qualified and eligible under this Article, without the
execution or filing of any paper or any further act on the part of any of the Parties
hereto. In case any Securities shall have been authenticated, but not delivered, by the
Trustee then in office, any successor by merger, conversion, sale or consolidation to such
authenticating Trustee may adopt such authentication and deliver the Securities so authenticated
with the same effect as if such successor Trustee had itself authenticated such Securities; and
such certificate shall have the full force which it is anywhere in the Securities or in this CVR
Agreement provided that the certificate of the Trustee shall have; provided that the right to adopt
the certificate of authentication of any predecessor Trustee shall apply only to its successor or
successors by merger, conversion or consolidation.

Section 4.13 Preferential Collection of Claims Against Company. If and when the
Trustee shall be or shall become a creditor, directly or indirectly, secured or unsecured, of the
Company (or any other obligor upon the Securities), excluding any creditor relationship set forth
in Section 311(b) of the Trust Indenture Act, if applicable, the Trustee shall be subject to the
applicable provisions of the Trust Indenture Act regarding the collection of claims against the
Company (or any such other obligor).

ARTICLE 5

HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY

Section 5.1 Company to Furnish Trustee Names and Addresses of Holders. The Company
will furnish or cause to be furnished to the Trustee (i) promptly after the issuance of the
Securities, and semi-annually thereafter, a list, in such form as the Trustee may reasonably
require, of the names and addresses of the Holders as of a recent date, and (ii) at such times as
the Trustee may request in writing, within thirty (30) days after receipt by the Company of any
such request, a list, in such form as the Trustee may reasonably require, of the names and
addresses of the Holders as of a date not more than fifteen (15) days prior to the time such list
is furnished; provided, however, that if and so long as the Trustee shall be the Security
Registrar, no such list need be furnished.

 

28

 

Section 5.2 Preservation of Information; Communications to Holders.

(a) The Trustee shall preserve, in as current a form as is reasonably practicable, the names
and addresses of Holders contained in the most recent list furnished to the Trustee as provided in
Section 5.1 and the names and addresses of Holders received by the Trustee in its capacity as
Security Registrar. The Trustee may destroy any list furnished to it as provided in Section 5.1
upon receipt of a new list so furnished.

(b) The rights of the Holders to communicate with other Holders with respect to their rights
under this CVR Agreement and the corresponding rights and privileges of the Trustee shall be as
provided by Section 312(b)(2) of the Trust Indenture Act, if applicable.

(c) Every Holder of Securities, by receiving and holding the same, agrees with the Company and
the Trustee that neither the Company nor the Trustee shall be deemed to be in violation of Law or
held accountable by reason of the disclosure of any such information as to the names and addresses
of the Holders made pursuant to the Trust Indenture Act (if applicable) regardless of the source
from which such information was derived.

Section 5.3 Reports by Trustee.

(a) Within sixty (60) days after December 31 of each year commencing with the December 31
following the date of this CVR Agreement, the Trustee shall transmit to all Holders such reports
concerning the Trustee and its actions under this CVR Agreement as may be required pursuant to the
Trust Indenture Act to the extent and in the manner provided pursuant thereto. The Trustee shall
also comply with Section 313(b)(2) of the Trust Indenture Act, if applicable. The Trustee shall
also transmit by mail all reports as required by Section 313(c) of the Trust Indenture Act, if
applicable.

(b) A copy of each such report shall, at the time of such transmission to the Holders, be
filed by the Trustee with each stock exchange, if any, upon which the Securities are listed, with
the Commission and also with the Company. The Company will promptly notify the Trustee when the
Securities are listed on any stock exchange.

Section 5.4 Reports by Company. The Company shall: (a) file with the Trustee, (i)
within fifteen (15) days after the Company is required to file the same with the Commission, copies
of the annual and quarterly reports and of the information, documents and other reports (or copies
of such portions of any of the foregoing as the Commission may from time to time by rules and
regulations prescribe) which the Company is required to file with the Commission pursuant to
Section 13 or Section 15(d) of the Exchange Act (such required information, documents and other
reports, together the “Exchange Act Documents”); and (ii) if the Company is not required to
file Exchange Act Documents under Section 13 or 15(d) of the Exchange Act, within forty-five (45)
days after each calendar quarter of the Company (other than the last quarter of each calendar
year), quarterly financial information and, within ninety (90) days after each calendar year of the
Company, annual financial information that would be required pursuant to Section 13 of the Exchange
Act in respect of a security listed and registered on a national securities exchange as may be
prescribed from time to time in such rules and regulations (provided that the Company also delivers
with,

 

29

 

or includes within, the annual reports referred to in (i) and (ii) a calculation of Net Sales
for the Products for the annual period to date), (iii) within ten (10) days after the Company files
its annual report with the Commission for any year if the Company is required to file Exchange Act
Documents under Section 13 or 15(d) of the Exchange Act, or if the Company is not required to file
Exchange Act Documents under Section 13 or 15(d) of the Exchange Act within ninety (90) days after
each calendar year, a Net Sales Statement with respect to the last completed calendar year, and
(iv) within four (4) Business Days after the occurrence of any Milestone, a notice setting forth
the Milestone that occurred, the amount of the Milestone Payment payable in connection therewith
and the applicable Milestone Payment Date; (b) file with the Trustee such additional information,
documents and reports with respect to compliance by the Company with the conditions and covenants
of this CVR Agreement as may be required from time to time by the rules and regulations of the
Commission, and (c) make available to the Holders on the Company’s website as of an even date with
the filing of such materials with the Trustee, the information, documents and reports required to
be filed by the Company pursuant to subsections (a) or (b) of this Section 5.4.

ARTICLE 6

AMENDMENTS

Section 6.1 Amendments Without Consent of Holders. Without the consent of any
Holders, the Company and the Trustee, at any time and from time to time, may enter into one or more
amendments hereto or to the Securities, for any of the following purposes:

(a) to convey, transfer, assign, mortgage or pledge to the Trustee as security for the
Securities any property or assets; or

(b) to evidence the succession of another Person to the Company, and the assumption by any
such successor of the covenants of the Company herein and in the Securities; or

(c) to add to the covenants of the Company such further covenants, restrictions, conditions or
provisions as its Board of Directors and the Trustee shall consider to be for the protection of the
Holders of Securities, and to make the occurrence, or the occurrence and continuance, of a default
in any such additional covenants, restrictions, conditions or provisions an Event of Default
permitting the enforcement of all or any of the several remedies provided in this CVR Agreement as
herein set forth; provided, that in respect of any such additional covenant, restriction, condition
or provision, such amendment may provide for a particular period of grace after default (which
period may be shorter or longer than that allowed in the case of other defaults) or may provide for
an immediate enforcement upon such an Event of Default or may limit the remedies available to the
Trustee upon such an Event of Default or may limit the right of the Majority Holders to waive such
an Event of Default; or

(d) to cure any ambiguity, or to correct or supplement any provision herein or in the
Securities which may be defective or inconsistent with any other provision herein; provided, that
such provisions shall not materially reduce the benefits of this CVR Agreement or the Securities to
the Holders; or

 

30

 

(e) to make any other provisions with respect to matters or questions arising under this CVR
Agreement; provided, that such provisions shall not adversely affect the interests of the Holders;

(f) to make any amendments or changes necessary to comply or maintain compliance with the
Trust Indenture Act, if applicable; or

(g) make any change that does not adversely affect the interests of the Holders.

(h) Promptly following any amendment of this CVR Agreement or the Securities in accordance
with this Section 6.1, the Trustee shall notify the Holders of the Securities of such amendment;
provided that any failure so to notify the Holders shall not affect the validity of such amendment.

Section 6.2 Amendments with Consent of Holders. With the consent of the Majority
Holders, by Act of said Holders delivered to the Company and the Trustee, the
Company (when authorized by a Board Resolution) and the Trustee may enter into one or more
amendments hereto or to the Securities for the purpose of adding any provisions to or changing in
any manner or eliminating any of the provisions of this CVR Agreement or to the Securities or of
modifying in any manner the rights of the Holders under this CVR Agreement or to the Securities;
provided, however, that no such amendment shall, without the consent of the Holder of each
Outstanding Security affected thereby:

(a) modify in a manner adverse to the Holders (i) any provision contained herein with respect
to the termination of this CVR Agreement or the Securities, (ii) the time for payment and amount of
any Net Sales Payment or any Milestone Payment, or otherwise extend the time for payment of the
Securities or reduce the amounts payable in respect of the Securities or modify any other payment
term or payment date. Notwithstanding the foregoing, each Holder of a Security, by acceptance
thereof, consents to the optional redemption provisions set forth in Article 11 hereof;

(b) reduce the number of CVRs, the consent of whose Holders is required for any such
amendment; or

(c) modify any of the provisions of this Section, except to increase any such percentage or to
provide that certain other provisions of this CVR Agreement cannot be modified or waived without
the consent of the Holder of each Security affected thereby.

It shall not be necessary for any Act of Holders under this Section to approve the particular
form of any proposed amendment, but it shall be sufficient if such Act shall approve the substance
thereof.

Section 6.3 Execution of Amendments. In executing any amendment permitted by this
Article, the Trustee (subject to Section 4.1) shall be fully protected in relying upon an Opinion
of Counsel stating that the execution of such amendment is authorized or permitted by this CVR
Agreement. The Trustee shall execute any amendment authorized pursuant to this Article if the
amendment does not adversely affect the Trustee’s own rights, duties or immunities under this CVR
Agreement or otherwise. Otherwise, the Trustee may, but need not, execute such amendment.

 

31

 

Section 6.4 Effect of Amendments; Notice to Holders.

(a) Upon the execution of any amendment under this Article, this CVR Agreement and the
Securities shall be modified in accordance therewith, and such amendment shall form a part of this
CVR Agreement and the Securities for all purposes; and every Holder of Securities theretofore or
thereafter authenticated and delivered hereunder shall be bound thereby.

(b) Promptly after the execution by the Company and the Trustee of any amendment pursuant to
the provisions of this Article, the Company shall mail a notice thereof by first class mail to the
Holders of Securities at their addresses as they shall appear on the Security Register, setting
forth in general terms the substance of such amendment. Any failure of the Company to mail such
notice, or any defect therein, shall not, however, in any way impair or affect the validity of any
such amendment.

Section 6.5 Conformity with Trust Indenture Act. Every amendment executed pursuant to
this Article shall conform to the applicable requirements of the Trust Indenture Act, if any.

Section 6.6 Reference in Securities to Amendments. If an amendment changes the terms
of a Security, the Trustee may require the Holder of the Security to deliver it to the Trustee.
Securities authenticated and delivered after the execution of any amendment pursuant to this
Article may, and shall if required by the Trustee, bear a notation in form approved by the Trustee
as to any matter provided for in such amendment. If the Company shall so determine, new Securities
so modified as to conform, in the opinion of the Trustee and the Board of Directors, to any such
amendment may be prepared and executed by the Company and authenticated and delivered by the
Trustee in exchange for Outstanding Securities. Failure to make the appropriate notation or to
issue a new Security shall not affect the validity of such amendment.

ARTICLE 7

COVENANTS

Section 7.1 Payment of Amounts, if any, to Holders. The Company will duly and
punctually pay the amounts, if any, on the Securities in accordance with the terms of the
Securities and this CVR Agreement. Such amounts shall be considered paid on the applicable Payment
Date if on such date the Trustee or the Paying Agent holds in accordance with this CVR Agreement
money sufficient to pay all such amounts then due. Notwithstanding any other provision of this CVR
Agreement, the Company or any of its Affiliates (including the Surviving Corporation, as
applicable), the Trustee or the Paying Agent, shall be entitled to deduct and withhold, or cause to
be deducted and withheld, from amounts (including CVRs) otherwise payable pursuant to this CVR
Agreement or the Merger Agreement to any holder of shares of Common Stock, Options, SARs, RSUs or
CVRs, such amounts as the Company or any of its Affiliates, the Trustee or the Paying Agent is
required to deduct and withhold with respect to the making of such payment under the Internal
Revenue Code of 1986, as amended, or any provision of state, local or foreign Tax Law. To the
extent that amounts are so withheld by the Company or any of its Affiliates, the Trustee or the
Paying Agent, such withheld amounts shall be (a) paid over to the applicable Governmental Entity in
accordance with applicable Law and (b) treated for all purposes of this CVR Agreement as having
been paid to such Holder in respect of which such deduction and withholding was made by the Company
or any of its Affiliates, the Trustee or the Paying Agent, as the case may be. The consent of
Holder shall not be required for any such withholding.

 

32

 

Section 7.2 Maintenance of Office or Agency.

(a) As long as any of the Securities remain Outstanding, the Company will maintain in the
Borough of Manhattan, The City of New York, an office or agency (i) where Securities may be
presented or surrendered for payment, (ii) where Securities may be surrendered for registration of
transfer or exchange and (iii) where notices and demands to or upon the Company in respect of the
Securities and this CVR Agreement may be served. The office or agency of the Trustee at [•] shall
be such office or agency of the Company, unless the Company shall designate and maintain some other
office or agency for one or more of such
purposes. The Company or any of its Subsidiaries may act as Paying Agent, registrar or
transfer agent; provided that such Person shall take appropriate actions to avoid the commingling
of funds. The Company will give prompt written notice to the Trustee of any change in the location
of any such office or agency. If at any time the Company shall fail to furnish the Trustee with
the address thereof, such presentations, surrenders, notices and demands may be made or served at
the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent
to receive all such presentations, surrenders, notices and demands.

(b) The Company may from time to time designate one or more other offices or agencies (in or
outside of The City of New York) where the Securities may be presented or surrendered for any or
all such purposes, and may from time to time rescind such designation; provided, however, that no
such designation or rescission shall in any manner relieve the Company of its obligation to
maintain an office or agency in the Borough of Manhattan, The City of New York for such purposes.
The Company will give prompt written notice to the Trustee of any such designation or rescission
and any change in the location of any such office or agency.

Section 7.3 Money for Security Payments to Be Held in Trust.

(a) If the Company or any of its Subsidiaries shall at any time act as the Paying Agent, it
will, on or before the Payment Date, as the case may be, segregate and hold in trust for the
benefit of the Holders all sums held by such Paying Agent for payment on the Securities until such
sums shall be paid to the Holders as herein provided, and will promptly notify the Trustee of any
default by the Company in making payment on the Securities.

(b) Whenever the Company shall have one or more Paying Agents for the Securities, it will, on
or before a Payment Date deposit with a Paying Agent a sum in same day funds sufficient to pay the
amount, if any, so becoming due; such sum to be held in trust for the benefit of the Persons
entitled to such amount, and (unless such Paying Agent is the Trustee) the Company will promptly
notify the Trustee of such action or any failure so to act.

 

33

 

(c) The Company will cause each Paying Agent other than the Trustee to execute and deliver to
the Trustee an instrument in which such Paying Agent shall agree with the Trustee, subject to the
provisions of this Section, that (i) such Paying Agent will hold all sums held by it for the
payment of any amount payable on Securities in trust for the benefit of the Persons entitled
thereto until such sums shall be paid to such Persons or otherwise disposed of as herein provided
and will notify the Trustee of the sums so held and (ii) that it will give the Trustee notice of
any failure by the Company (or by any other obligor on the Securities) to make any payment on the
Securities when the same shall be due and payable.

(d) Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in
trust for the payment on any Security and remaining unclaimed for one year after the Payment Date
shall be paid to the Company on Company Request, or (if then held by the Company) shall be
discharged from such trust; and the Holder of such Security shall thereafter, as an unsecured
general creditor, look only to the Company for payment thereof, and all liability of the Trustee or
such Paying Agent with respect to such trust money shall thereupon cease.

Section 7.4 Certain Purchases and Sales. Nothing contained herein shall prohibit the
Company or any of its Subsidiaries or Affiliates from acquiring in open market transactions,
private transactions or otherwise, the Securities.

Section 7.5 Books and Records. The Company shall keep, and shall cause its
Subsidiaries to keep, true, complete and accurate records in sufficient detail to enable the
amounts payable under this CVR Agreement to be determined by the Holders and their consultants or
professional advisors, for a period of three (3) years following the end of any Net Sales Measuring
Period.

Section 7.6 Audits.

(a) Upon the written request of the Majority Holders and no more than once during any calendar
year, and upon reasonable notice, the Company shall provide an independent certified public
accounting firm of nationally recognized standing selected by the Majority Holders and the Company
(the “Independent Accountant”) with access during normal business hours to such of the
records of the Company as may be reasonably necessary to verify the accuracy of the Net Sales
Statements and the figures underlying the calculations set forth therein for any period within the
preceding three (3) years that has not previously been audited in accordance with this Section 7.6.
The Company shall pay for the fees charged by the Independent Accountant in the event that the
Independent Accountant determines that the amount paid by the Company is more than ten percent
(10%) below the amount due; provided, however, that the Majority Holders shall pay for the fees
charged by such Independent Accountant in the event that the Independent Accountant determines that
the amount paid by the Company is equal to or less than ten percent (10%) below the amount due,
which amount the Company may deduct from any future CVR Payments payable pursuant to this CVR
Agreement. The Independent Accountant shall disclose to the Majority Holders only the amounts that
the Independent Accountant believes to be due and payable by the Company, details concerning any
discrepancy from the amount paid and the amount due, and shall disclose no other information
revealed in such audit. The Independent Accountant shall provide the Company with a copy of all
disclosures made to the Majority Holders. This covenant shall survive the termination of this CVR
Agreement for a period of three (3) years; provided that the Holders shall only be entitled to one
audit following termination of this CVR Agreement.

 

34

 

(b) If the Independent Accountant concludes that any Net Sales Payment amount should have been
greater than the Net Sales Payment set forth in an applicable Net Sales Statement (the difference
being the “CVR Shortfall”), the Company shall pay the CVR Shortfall, within six (6) months
of the date the Majority Holders deliver to the Company the Independent Accountant’s written report
(the “Shortfall Report”); provided that the CVR Shortfall amount shall bear interest at the
Shortfall Interest Rate beginning from thirty (30) days after the date the Majority Holders deliver
to the Company the Shortfall Report until payment is made to the Trustee. The decision of such
Independent Accountant shall be final, conclusive and binding on the Company and the Holders, shall
be non-appealable and shall not be subject to further review.

(c) Upon the expiration of three (3) years following the end of any Net Sales Measuring
Period, the calculation of the Net Sales Payment payable with respect to such Net Sales Measuring
Period shall be conclusive and binding on each Holder, and the Company shall
be released from any liability or accountability with respect to payments in respect of such
Net Sales Measuring Period in excess of such Net Sales Payment.

(d) Each person seeking to receive information from the Company in connection with a review or
audit shall enter into, and shall cause its accounting firm to enter into, a reasonable and
mutually satisfactory confidentiality agreement with the Company obligating such party to retain
all such financial information disclosed to such party in confidence pursuant to such
confidentiality agreement.

(e) The Company shall not, and shall cause its Affiliates not to, enter into any license or
distribution agreement with any third party (other than the Company or its Affiliates) with respect
to any Product unless such agreement contains provisions that would allow any Independent
Accountant appointed pursuant to this Section 7.6 such access to the records of the other party to
such license or distribution agreement as may be reasonably necessary to perform its duties
pursuant to this Section 7.6; provided that the Company and its Affiliates shall not be required to
amend any Existing Licenses. The Parties agree that, if the Company or its Affiliates have
exercised audit rights under any license or distribution agreement prior to the Majority Holders’
request for an audit under this Section 7.6 and under such license or distribution agreement the
Company and its Affiliates cannot request another audit, the results of the Company’s prior audit
of such licensee or distributor will be used for purposes of the audit requested by the Majority
Holders under this Section 7.6 and that the Company shall not have any further obligation to
provide access to an Independent Accountant with respect to such licensee until such time as the
Company may again exercise its rights of audit under the license agreement with such licensee.

Section 7.7 Listing of CVRs. The Company hereby covenants and agrees to use
reasonable best efforts to cause the Securities to be approved for listing (subject to notice of
issuance) for trading on the Nasdaq Capital Market and will use its reasonable best efforts to
maintain such listing for so long as any CVRs remain Outstanding.

 

35

 

Section 7.8 Conflicting Arrangements. So long as any of the Securities remain
Outstanding, the Company shall not enter into any binding agreement, arrangement or understanding,
or take or permit to be taken any action, which would, or would reasonably be expected to, delay or
prevent the Company’s ability to timely make any CVR Payment that becomes due under this CVR
Agreement.

Section 7.9 Product Transfer. Subject to Article 9, so long as the Securities remain
Outstanding, the Company and its Affiliates may not, directly or indirectly, by a sale or swap of
assets, merger, reorganization, joint venture, lease, license or any other transaction or
arrangement, sell, transfer, convey or otherwise dispose of their respective rights in and to any
Product to a third party (other than the Company or its Affiliates), unless at all times after any
such sale, transfer, conveyance or other disposition, the gross amounts invoiced for the Products
by the applicable transferee (or the amounts of royalties, profit split payments and milestone
payments, as described in clause (ii) of the definition of “Net Sales,” with respect to Existing
Licenses, as applicable) will be reflected in Net Sales in accordance with the terms hereunder
(with the transferee substituted for the Company for purposes of the definition of “Net Sales”) as
if such transferee was the Company, and the contract for such sale, transfer, conveyance or other
disposition (which the Company shall take all reasonable actions necessary to enforce in all
material respects) shall provide for such treatment and shall require the transferee to comply with
the covenants in this Section 7.9 and Sections 7.6, 7.10 and 7.11 hereof to the same extent as the
Company. For purposes of clarification, this Section 7.9 shall not apply to sales of Products made
by the Company or its Affiliates or ordinary course licensing arrangements between the Company and
its Affiliates, on the one hand, and third party licensees, distributors and contract
manufacturers, on the other hand, entered into in the ordinary course of business for purposes of
developing, manufacturing, distributing and selling Products and for which the gross amounts
invoiced for sales of Products by the applicable third party licensee, distributor or contract
manufacturer (or the amounts of royalties, profit split payments and milestone payments, as
described in clause (ii) of the definition of “Net Sales,” with respect to Existing Licenses, as
applicable) will be reflected in Net Sales of such Products in accordance with the terms of this
Agreement.

Section 7.10 Milestones. The Company shall use Diligent Efforts to achieve each of
the Milestones; provided, however, that such obligation to use Diligent Efforts to achieve each of
the Milestones shall terminate upon the Milestone Target Date.

Section 7.11 Product Sale and Development. The Company shall use Diligent Efforts to
obtain Regulatory Approval for the Indications; provided, however, that such obligation to use
Diligent Efforts to obtain such Regulatory Approval shall terminate upon the earlier of (a) the Net
Sales Payment Termination Date and (b) on an Indication-by-Indication basis, such time as the data
generated in an appropriate clinical trial does not support further development of the Product
described in clause (a) of the definition of “Product.” The Company shall use Diligent Efforts to
sell the Products for which the Company has obtained Regulatory Approval; provided, however, that
such obligation to use Diligent Efforts to sell the Products shall terminate upon the Net Sales
Payment Termination Date.

 

36

 

Section 7.12 Notice of Default. The Company shall file with the Trustee written
notice of the occurrence of any Event of Default or other default under this CVR Agreement within
five (5) business days of its becoming aware of any such Default or Event of Default.

Section 7.13 Confidentiality. The Trustee and the Holders hereby agree that any
confidential or non-public information (including Net Sales Statements) they receive from or on
behalf of the Company or any Affiliate of the Company, which receipt arises out of the transactions
contemplated by this CVR Agreement (the “Confidential Information”), shall: (a) not be used
for any purpose other than for purposes permitted under this CVR Agreement; (b) not be used
directly or indirectly in any way that is for competitive purposes; and (c) not be disclosed by,
and be kept confidential by, such Trustee and the Holders and its directors, officers, members,
managers, employees, affiliates, and agents (collectively, “Representatives”); provided,
however, that any such Confidential Information may be disclosed only to their Representatives
(including the Independent Accountant) who (i) need to know such Confidential Information and (ii)
are bound in writing to a non-disclosure agreement no less restrictive than this Section 7.13. It
is understood that such Representatives shall be informed by the Trustee or the applicable Holder
of the confidential nature of such Confidential Information, and that the Trustee or such Holder,
as applicable, shall be responsible for any disclosure or use made by its Representatives in breach
of obligations under this CVR Agreement to the same extent as if such
disclosure or use had been made directly by the Trustee or such Holder, as applicable. Each
of the Trustee and the Holders will as soon as practicable notify the Company of any breach of this
CVR Agreement of which they become aware, and will use commercially reasonable efforts to assist
and cooperate with the Company in minimizing the consequences of such breach. “Confidential
Information” shall not include any information that is (i) publicly available other than because of
disclosure by the Trustee or the Holders or any of their respective Representatives or (ii) is
lawfully disclosed to the Trustee or Holders by sources (other than the Company or its Affiliates)
rightfully in possession of the Confidential Information. If the Trustee, Holders or their
respective Representatives are legally required or requested to disclose any Confidential
Information, they will in advance of such disclosure, unless otherwise prohibited by Law, promptly
notify the Company of such request or requirement so that the Company may seek to avoid or minimize
the required disclosure and/or obtain an appropriate protective order or other appropriate relief
to ensure that any Confidential Information so disclosed is maintained in confidence to the maximum
extent possible by the person receiving the disclosure, or, in the Company’s discretion, to waive
compliance with the provisions of this CVR Agreement. In any such case, the Trustee and the
Holders agree to cooperate and use reasonable efforts to avoid or minimize the required disclosure
and/or obtain such protective order or other relief. If, in the absence of a protective order or
the receipt of a waiver hereunder, the Trustee, Holders or their respective Representatives are
legally obligated to disclose any Confidential Information, they will disclose only so much thereof
to the party compelling disclosure as they believe in good faith, on the basis of advice of
counsel, is required by Law. The Trustee and Holders shall give the Company prior written notice
of the specific Confidential Information that they believe they are required to disclose under such
circumstances. All Confidential Information disclosed by or on behalf of the Company or any of its
Affiliates shall be, and shall remain, the property of the Company or such Affiliate.

Section 7.14 Non-Use of Name. Neither the Trustee nor the Holders shall use the name,
trademark, trade name, or logo of the Company, its Affiliates, or their respective employees in any
publicity or news release relating to this CVR Agreement or its subject matter, without the prior
express written permission of the Company.

 

37

 

ARTICLE 8

REMEDIES OF THE TRUSTEE AND HOLDERS

ON EVENT OF DEFAULT

Section 8.1 Event of Default Defined; Waiver of Default. “Event of Default”
with respect to the Securities, means each one of the following events which shall have occurred
and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary
or involuntary or be effected by operation of Law or pursuant to any judgment, decree or order of
any court or any order, rule or regulation of any administrative or governmental body):

(a) default in the payment of all or any part of any CVR Payment after a period of ten (10)
Business Days after such CVR Payment shall become due and payable on a Payment Date or otherwise;
or

(b) material default in the performance, or breach in any material respect, of any covenant or
warranty of the Company in respect of the Securities (other than a covenant or warranty in respect
of the Securities, a default in whose performance or whose breach is elsewhere in this Section
specifically dealt with), and continuance of such default or breach for a period of ninety (90)
days after there has been given, by registered or certified mail, to the Company by the Trustee or
to the Company and the Trustee by the Majority Holders, a written notice specifying such default or
breach and requiring it to be remedied and stating that such notice is a “Notice of Default”
hereunder; or

(c) a court having jurisdiction in the premises shall enter a decree or order for relief in
respect of the Company in an involuntary case under any applicable bankruptcy, insolvency or other
similar Law now or hereafter in effect, or appointing a receiver, liquidator, assignee, custodian,
trustee or sequestrator (or similar official) of the Company or for any substantial part of its
property or ordering the winding up or liquidation of its affairs, and such decree or order shall
remain unstayed and in effect for a period of ninety (90) consecutive days; or

(d) the Company shall commence a voluntary case under any applicable bankruptcy, insolvency or
other similar Law now or hereafter in effect, or consent to the entry of an order for relief in an
involuntary case under any such Law, or consent to the appointment of or taking possession by a
receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) of the
Company or for any substantial part of its property, or make any general assignment for the benefit
of creditors.

If an Event of Default described above occurs and is continuing, then, and in each and every
such case, either the Trustee or the Trustee upon the written request of the Majority Holders by
notice in writing to the Company (and to the Trustee if given by the Majority Holders), shall bring
suit to protect the rights of the Holders, including to obtain payment for any amounts then due and
payable, which amounts shall bear interest at the Default Interest Rate until payment is made to
the Trustee.

 

38

 

The foregoing provisions, however, are subject to the condition that if, at any time after the
Trustee shall have begun such suit, and before any judgment or decree for the payment of the moneys
due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall
deposit with the Trustee a sum sufficient to pay all amounts which shall have become due (with
interest upon such overdue amount at the Default Interest Rate to the date of such payment or
deposit) and such amount as shall be sufficient to cover reasonable compensation to the Trustee,
its agents, attorneys and counsel, and all other expenses and liabilities incurred and all advances
made, by the Trustee, and if any and all Events of Default under this CVR Agreement shall have been
cured, waived or otherwise remedied as provided herein, then and in every such case the Majority
Holders, by written notice to the Company and to the Trustee, may waive all defaults with respect
to the Securities, but no such waiver or rescission and annulment shall extend to or shall affect
any subsequent default or shall impair any right consequent thereof.

Section 8.2 Collection by the Trustee; the Trustee May Prove Payment Obligations. The
Company covenants that in case default shall be made in the payment of all or
any part of the Securities when the same shall have become due and payable, whether at a
Payment Date or otherwise, then upon demand of the Trustee, the Company will pay to the Trustee for
the benefit of the Holders of the Securities the whole amount that then shall have become due and
payable on all Securities (with interest from the date due and payable to the date of such payment
upon the overdue amount at the Default Interest Rate); and in addition thereto, such further amount
as shall be sufficient to cover the costs and expenses of collection, including reasonable
compensation to the Trustee and each predecessor Trustee, their respective agents, attorneys and
counsel, and any expenses and liabilities incurred, and all advances made, by the Trustee and each
predecessor Trustee, except as a result of its negligence or bad faith.

The Trustee may in its discretion proceed to protect and enforce its rights and the rights of
the Holders by such appropriate judicial proceedings as the Trustee shall deem most effectual to
protect and enforce any such rights, whether for the specific enforcement of any covenant or
agreement in this CVR Agreement or in aid of the exercise of any power granted herein, or to
enforce any other remedy.

In case the Company shall fail forthwith to pay such amounts upon such demand, the Trustee, in
its own name and as trustee of an express trust, shall be entitled and empowered to institute any
action or proceedings at Law or in equity for the collection of the sums so due and unpaid, and may
prosecute any such action or proceedings to judgment or final decree, and may enforce any such
judgment or final decree against the Company or other obligor upon such Securities and collect in
the manner provided by Law out of the property of the Company or other obligor upon such
Securities, wherever situated, the moneys adjudged or decreed to be payable.

 

39

 

In any judicial proceedings relative to the Company or other obligor upon the Securities,
irrespective of whether any amount is then due and payable with respect to the Securities, the
Trustee is authorized:

(a) to file and prove a claim or claims for the whole amount owing and unpaid in respect of
the Securities, and to file such other papers or documents as may be necessary or advisable in
order to have the claims of the Trustee (including any claim for reasonable compensation to the
Trustee and each predecessor Trustee, and their respective agents, attorneys and counsel, and for
reimbursement of all expenses and liabilities incurred, and all advances made, by the Trustee and
each predecessor Trustee, except as a result of negligence or bad faith) and of the Holders allowed
in any judicial proceedings relative to the Company or other obligor upon the Securities, or to
their respective property;

(b) unless prohibited by and only to the extent required by applicable Law, to vote on behalf
of the Holders in any election of a trustee or a standby trustee in arrangement, reorganization,
liquidation or other bankruptcy or insolvency proceedings or person performing similar functions in
comparable proceedings; and

(c) to collect and receive any moneys or other property payable or deliverable on any such
claims, and to distribute all amounts received with respect to the claims of the Holders and of the
Trustee on their behalf; and any trustee, receiver, or liquidator, custodian or other similar
official is hereby authorized by each of the Holders to make payments to the
Trustee, and, in the event that the Trustee shall consent to the making of payments directly
to the Holders, to pay to the Trustee such amounts as shall be sufficient to cover reasonable
compensation to the Trustee, each predecessor Trustee and their respective agents, attorneys and
counsel, and all other expenses and liabilities incurred, and all advances made, by the Trustee and
each predecessor Trustee, except as a result of its negligence or bad faith, and all other amounts
due to the Trustee or any predecessor Trustee pursuant to Section 4.6. To the extent that such
payment of reasonable compensation, expenses, disbursements, advances and other amounts out of the
estate in any such proceedings shall be denied for any reason, payment of the same shall be secured
by a lien on, and shall be paid out of, any and all distributions, dividends, moneys, securities
and other property which the Holders may be entitled to receive in such proceedings, whether in
liquidation or under any plan of reorganization or arrangement or otherwise.

Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to
or vote for or accept or adopt on behalf of any Holder any plan of reorganization, arrangement,
adjustment or composition affecting the Securities, or the rights of any Holder thereof, or to
authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding except,
as aforesaid, to vote for the election of a trustee in bankruptcy or similar person.

All rights of action and of asserting claims under this CVR Agreement, or under any of the
Securities, may be enforced by the Trustee without the possession of any of the Securities or the
production thereof and any trial or other proceedings instituted by the Trustee shall be brought in
its own name as trustee of an express trust, and any recovery of judgment, subject to the payment
of the expenses, disbursements and compensation of the Trustee, each predecessor Trustee and their
respective agents and attorneys, shall be for the ratable benefit of the Holders.

 

40

 

In any proceedings brought by the Trustee (and also any proceedings involving the
interpretation of any provision of this CVR Agreement to which the Trustee shall be a party) the
Trustee shall be held to represent all the Holders, and it shall not be necessary to make any
Holders of such Securities parties to any such proceedings.

Section 8.3 Application of Proceeds. Any monies collected by the Trustee pursuant to
this Article in respect of any Securities shall be applied in the following order at the date or
dates fixed by the Trustee upon presentation of the several Securities in respect of which monies
have been collected and stamping (or otherwise noting) thereon the payment in exchange for the
presented Securities if only partially paid or upon surrender thereof if fully paid:

FIRST: To the payment of costs and expenses in respect of which monies have been
collected, including reasonable compensation to the Trustee and each predecessor Trustee and
their respective agents and attorneys and of all expenses and liabilities incurred, and all
advances made, by the Trustee and each predecessor Trustee, except as a result of its
negligence or willful misconduct, and all other amounts due to the Trustee or any
predecessor Trustee pursuant to Section 4.6;

SECOND: To the payment of the whole amount then owing and unpaid upon all the
Securities, with interest at the Default Interest Rate on all such amounts, and in case such
monies shall be insufficient to pay in full the whole amount so due and unpaid upon the
Securities, then to the payment of such amounts without preference or priority of any
security over any other Security, ratably to the aggregate of such amounts due and payable;
and

THIRD: To the payment of the remainder, if any, to the Company or any other person
lawfully entitled thereto.

Section 8.4 Suits for Enforcement. In case an Event of Default has occurred, has not
been waived and is continuing, the Trustee may in its discretion proceed to protect and enforce the
rights vested in it by this CVR Agreement by such appropriate judicial proceedings as the Trustee
shall deem most effectual to protect and enforce any of such rights, either at Law or in equity or
in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement
contained in this CVR Agreement or in aid of the exercise of any power granted in this CVR
Agreement or to enforce any other legal or equitable right vested in the Trustee by this CVR
Agreement or by Law.

Section 8.5 Restoration of Rights on Abandonment of Proceedings. In case the Trustee
or any Holder shall have proceeded to enforce any right under this CVR Agreement and such
proceedings shall have been discontinued or abandoned for any reason, or shall have been determined
adversely to the Trustee or to such Holder, then and in every such case the Company and the Trustee
and the Holders shall be restored respectively to their former positions and rights hereunder, and
all rights, remedies and powers of the Company, the Trustee and the Holders shall continue as
though no such proceedings had been taken.

 

41

 

Section 8.6 Limitations on Suits by Holders. Subject to the right of the Majority
Holders under Section 7.6, no Holder of any Security shall have any right by virtue or by availing
of any provision of this CVR Agreement to institute any action or proceeding at Law or in equity or
in bankruptcy or otherwise upon or under or with respect to this CVR Agreement, or for the
appointment of a trustee, receiver, liquidator, custodian or other similar official or for any
other remedy hereunder, unless such Holder previously shall have given to the Trustee written
notice of default and of the continuance thereof, as hereinbefore provided, and unless also the
Majority Holders shall have made written request upon the Trustee to institute such action or
proceedings in its own name as trustee hereunder and shall have offered to the Trustee such
reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred
therein or thereby and the Trustee for fifteen (15) days after its receipt of such notice, request
and offer of indemnity shall have failed to institute any such action or proceeding and no
direction inconsistent with such written request shall have been given to the Trustee pursuant to
Section 8.9. For the protection and enforcement of the provisions of this Section, each and every
Holder and the Trustee shall be entitled to such relief as can be given either at Law or in equity.

Section 8.7 Unconditional Right of Holders to Institute Certain Suits.
Notwithstanding any other provision in this CVR Agreement and any provision of any Security, the
right of any Holder of any Security to receive payment of the amounts payable in respect of such
Security on or after the respective due dates expressed in such Security, or to institute suit
for the enforcement of any such payment on or after such respective dates, shall not be
impaired or affected without the consent of such Holder.

Section 8.8 Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default.

(a) Except as provided in Section 8.6, no right or remedy herein conferred upon or reserved to
the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every
right and remedy shall, to the extent permitted by Law, be cumulative and in addition to every
other right and remedy given hereunder or now or hereafter existing at Law or in equity or
otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not
prevent the concurrent assertion or employment of any other appropriate right or remedy.

(b) No delay or omission of the Trustee or of any Holder to exercise any right or power
accruing upon any Event of Default occurring and continuing as aforesaid shall impair any such
right or power or shall be construed to be a waiver of any such Event of Default or an acquiescence
therein; and, subject to Section 8.6, every power and remedy given by this CVR Agreement or by Law
to the Trustee or to the Holders may be exercised from time to time, and as often as shall be
deemed expedient, by the Trustee or by the Holders.

Section 8.9 Control by Holders.

(a) The Majority Holders shall have the right to direct the time, method, and place of
conducting any proceeding for any remedy available to the Trustee, or exercising any power
conferred on the Trustee with respect to the Securities by this CVR Agreement; provided that such
direction shall not be otherwise than in accordance with Law and the provisions of this CVR
Agreement; and provided further that (subject to the provisions of Section 4.1) the Trustee shall
have the right to decline to follow any such direction if the Trustee, being advised by counsel,
shall determine that the action or proceeding so directed may not lawfully be taken or if the
Trustee in good faith by its board of directors, the executive committee, or a committee of
directors or responsible officers of the Trustee shall determine that the action or proceedings so
directed would involve the Trustee in personal liability or if the Trustee in good faith shall so
determine that the actions or forbearances specified in or pursuant to such direction would be
unduly prejudicial to the interests of Holders of the Securities not joining in the giving of said
direction.

 

42

 

(b) Nothing in this CVR Agreement shall impair the right of the Trustee in its discretion to
take any action deemed proper by the Trustee and which is not inconsistent with such direction or
directions by Holders.

Section 8.10 Waiver of Past Defaults.

(a) In the case of a default or an Event of Default specified in clause (b), (c) or (d) of
Section 8.1, the Majority Holders may waive any such default or Event of Default, and its
consequences except a default in respect of a covenant or provisions hereof which cannot be
modified or amended without the consent of the Holder of each Security affected. In the case of
any such waiver, the Company, the Trustee and the Holders of the Securities shall be restored to
their former positions and rights hereunder, respectively; but no such waiver shall extend to
any subsequent or other default or impair any right consequent thereon.

(b) Upon any such waiver, such default shall cease to exist and be deemed to have been cured
and not to have occurred, and any Event of Default arising therefrom shall be deemed to have been
cured, and not to have occurred for every purpose of this CVR Agreement; but no such waiver shall
extend to any subsequent or other default or Event of Default or impair any right consequent
thereon.

Section 8.11 The Trustee to Give Notice of Default, But May Withhold in Certain
Circumstances. The Trustee shall transmit to the Holders, as the names and addresses of such
Holders appear on the Security Register (as provided under Section 313(c) of the Trust Indenture
Act, if applicable), notice by mail of all defaults which have occurred and are known to the
Trustee, such notice to be transmitted within ninety (90) days after the occurrence thereof, unless
such defaults shall have been cured before the giving of such notice (the term “default” for the
purposes of this Section being hereby defined to mean any event or condition which is, or with
notice or lapse of time or both would become, an Event of Default); provided that, except in the
case of default in the payment of the amounts payable in respect of any of the Securities, the
Trustee shall be protected in withholding such notice if and so long as the board of directors, the
executive committee, or a trust committee of directors or trustees and/or Responsible Officers of
the Trustee in good faith determines that the withholding of such notice is in the interests of the
Holders.

Section 8.12 Right of Court to Require Filing of Undertaking to Pay Costs. All
Parties to this CVR Agreement agree, and each Holder of any Security by his acceptance thereof
shall be deemed to have agreed, that any court may in its discretion require, in any suit for the
enforcement of any right or remedy under this CVR Agreement or in any suit against the Trustee for
any action taken, suffered or omitted by it as the Trustee, the filing by any party litigant in
such suit of an undertaking to pay the costs of such suit, and that such court may in its
discretion assess reasonable costs, including attorneys’ fees, against any party litigant in such
suit, having due regard to the merits and good faith of the claims or defenses made by such party
litigant; but the provisions of this Section 8.12 shall not apply to any suit instituted by the
Trustee, to any suit instituted by any Holder or group of Holders holding in the aggregate more
than ten percent (10%) of the Securities Outstanding or to any suit instituted by any Holder for
the enforcement of the payment of any Security on or after the due date expressed in such Security.

 

43

 

ARTICLE 9

CONSOLIDATION, MERGER, SALE OR CONVEYANCE

Section 9.1 Company May Consolidate, etc., on Certain Terms. The Company covenants
that it will not merge or consolidate with or into any other Person or sell or convey all or
substantially all of its assets to any Person, unless, (i) the Company shall be the continuing
Person, or the successor Person or the Person which acquires by sale or conveyance substantially
all the assets of the Company (including the shares of Abraxis) shall be a Person organized under
the Laws of the United States of America or any State thereof and shall expressly assume by an
instrument supplemental hereto, executed and delivered to the Trustee, in form satisfactory to the
Trustee, the due and punctual payment of the Securities, according to their tenor, and the due and
punctual performance and observance of all of the covenants and conditions of this CVR
Agreement to be performed or observed by the Company and (ii) the Company, or such successor
Person, as the case may be, shall not, immediately after such merger or consolidation, or such sale
or conveyance, be in default in the performance of any such covenant or condition.

Section 9.2 Successor Person Substituted.

(a) In case of any such consolidation, merger, sale or conveyance, and following such an
assumption by the successor Person, such successor Person shall succeed to and be substituted for
the Company with the same effect as if it had been named herein. Such successor Person may cause
to be signed, and may issue either in its own name or in the name of the Company prior to such
succession any or all of the Securities issuable hereunder which theretofore shall not have been
signed by the Company and delivered to the Trustee; and, upon the order of such successor
corporation instead of the Company and subject to all the terms, conditions and limitations in this
CVR Agreement prescribed, the Trustee shall authenticate and shall deliver any Securities which
previously shall have been signed and delivered to the Trustee for authentication, and any
Securities which such successor corporation thereafter shall cause to be signed and delivered to
the Trustee for that purpose. All of the Securities so issued shall in all respects have the same
legal rank and benefit under this CVR Agreement as the Securities theretofore or thereafter issued
in accordance with the terms of this CVR Agreement as though all of such Securities had been issued
at the date of the execution hereof.

(b) In case of any such consolidation, merger, sale or conveyance, such changes in phraseology
and form (but not in substance) may be made in the Securities thereafter to be issued as may be
appropriate. The successor entity to such consolidation, merger, sale or conveyance may satisfy
the obligations of Section 5.4(a)(i) and (ii) of this CVR Agreement by providing copies of such
successor entity’s Exchange Act Documents in the case of Section 5.4(a)(i) or such successor
entity’s financial information in the case of Section 5.4(a)(ii).

 

44

 

(c) In the event of any such sale, transfer or conveyance (other than a conveyance by way of
lease) the Company or any Person which shall theretofore have become such in the manner described
in this Article shall be discharged from all obligations and covenants under this CVR Agreement and
the Securities and may be liquidated and dissolved.

Section 9.3 Opinion of Counsel to the Trustee. The Trustee, subject to the provisions
of Sections 4.1 and 4.2, shall receive an Officer’s Certificate and Opinion of Counsel, prepared in
accordance with Sections 1.3 and 1.4, as conclusive evidence that any such consolidation, merger,
sale or conveyance, and any such assumption, and any such liquidation or dissolution, complies with
the applicable provisions of this CVR Agreement, and if a supplemental agreement is required in
connection with such transaction, such supplemental agreement complies with this Article and that
there has been compliance with all conditions precedent herein provided for or relating to such
transaction.

Section 9.4 Successors. All covenants, provisions and agreements in this CVR
Agreement by or for the benefit of the Company, the Trustee or the Holders shall bind and inure to
the benefit of their respective successors, assigns, heirs and personal representatives, whether so
expressed or not. The Company may assign this CVR Agreement without the prior written
consent of the other Parties to this CVR Agreement to one or more of its direct or indirect
Subsidiaries, provided, however, that in the event of any such assignment the Company shall remain
subject to its obligations and covenants hereunder, including but not limited to its obligation to
make any Net Sales Payments and any Milestone Payments.

ARTICLE 10

SUBORDINATION

Section 10.1 Agreement to Subordinate. The Company agrees, and each Holder by
accepting a Security hereunder agrees, that the CVR Payments, all other obligations under this CVR
Agreement and the Securities and any rights or claims relating thereto (collectively, the
“Junior Obligations”) are subordinated in right of payment, to the extent and in the manner
provided in this Article 10, to the prior payment in full in cash or cash equivalents of all Senior
Obligations of the Company (whether outstanding on the date hereof or hereafter created, incurred,
assumed or guaranteed), and that the subordination is for the benefit of the holders of such Senior
Obligations.

Section 10.2 Liquidation; Dissolution; Bankruptcy. Upon any distribution to creditors
of the Company in a liquidation or dissolution of the Company or in a bankruptcy, reorganization,
insolvency, receivership or similar proceeding relating to the Company or its property, in an
assignment for the benefit of creditors or any marshaling of the Company’s assets and liabilities:

(a) holders of Senior Obligations will be entitled to receive payment in full in cash or cash
equivalents of all Senior Obligations of the Company (including interest after the commencement of
any bankruptcy proceeding at the rate specified in the applicable Senior Obligation, whether or not
permitted under such bankruptcy proceedings) before the Holders will be entitled to receive any
payment of any kind with respect to the Junior Obligations; and

 

45

 

(b) until all Senior Obligations of the Company (as provided in clause (a) above) are paid in
full in cash or cash equivalents, any distribution to which Holders would be entitled but for this
Article 10 will be made to holders of Senior Obligations of the Company, as their interests may
appear.

Section 10.3 Default on Senior Obligations. The Company may not make any payment or
distribution to any Holder in respect of Junior Obligations or acquire from any Holder for cash or
property any Junior Obligations:

(a) if any default on any Senior Obligations exceeding twenty-five million dollars
($25,000,000) in aggregate principal amount would occur as a result of such payment, distribution
or acquisition;

(b) during the continuance of any payment default in respect of any Senior Obligations (after
expiration of any applicable grace period) exceeding twenty-five million dollars ($25,000,000) in
aggregate principal amount;

(c) if the maturity of any Senior Obligations representing more than twenty-five million
dollars ($25,000,000) in aggregate principal amount is accelerated in accordance with its terms and
such acceleration has not been rescinded; or

(d) following the occurrence of any default (other than a payment default, and after the
expiration of any applicable grace period) with respect to any Senior Obligations with an aggregate
principal amount of more than twenty-five million dollars ($25,000,000), the effect of which is to
permit the holders of such Senior Obligations (or a trustee or agent acting on their behalf) to
cause, with the giving of notice if required, the maturity of such Senior Obligations to be
accelerated, for a period commencing upon the receipt by the Trustee (with a copy to the Company)
of a written notice of such default from the representative of the holders of such Senior
Obligations and ending when such Senior Obligations are paid in full in cash or cash equivalents
or, if earlier, when such default is cured or waived.

Section 10.4 When Distribution Must Be Paid Over.

(a) In the event that the Trustee or any Holder receives any payment of any Junior Obligations
at a time when such payment is prohibited by this Article 10, such payment will be held by the
Trustee or such Holder, in trust for the benefit of, and will be paid forthwith over and delivered,
upon written request, to, the holders of Senior Obligations of the Company as their interests may
appear or their representative under the agreement, indenture or other document (if any) pursuant
to which such Senior Obligations may have been issued, as their respective interests may appear,
for application to the payment of all such Senior Obligations remaining unpaid to the extent
necessary to pay such Senior Obligations in full in accordance with their terms, after giving
effect to any concurrent payment or distribution to or for the holders of Senior Obligations.

(b) Any amount received by any Holder as a result of direct or indirect credit support for the
Junior Obligations from any Affiliate of the Company shall be treated as payments received by such
Holder from the Company that are subject to the provisions of this Article 10.

 

46

 

(c) With respect to the holders of Senior Obligations, the Trustee undertakes to perform only
those obligations on the part of the Trustee as are specifically set forth in this Article 10, and
no implied covenants or obligations with respect to the holders of Senior Obligations will be read
into this CVR Agreement against the Trustee. The Trustee will not be deemed to owe any fiduciary
duty to the holders of Senior Obligations, and will not be liable to any such holders if the
Trustee pays over or distributes to or on behalf of Holders or the Company or any other Person
money or assets to which any holders of Senior Obligations are then entitled by virtue of this
Article 10, except if such payment is made as a result of the willful misconduct or gross
negligence of the Trustee.

Section 10.5 Notice by Company. The Company will promptly notify the Trustee of any
facts known to the Company that would cause a payment of any Junior Obligations to violate this
Article 10, but failure to give such notice will not affect the subordination of the Junior
Obligations to the Senior Obligations as provided in this Article 10.

Section 10.6 Subordination Effective Notwithstanding Deficiencies with Respect to Senior
Obligations; Waiver of Right to Contest Senior Obligation; Reinstatement of Subordination
Provisions.

(a) The Holders hereby agree that subordination provisions contained in this Article 10 are
unconditional, irrespective of the validity, regularity or enforceability of the Senior
Obligations, the absence of any action to enforce the same, any waiver or consent by any holder of
Senior Obligations with respect to any provisions thereof, the recovery of any judgment against the
Company, any action to enforce the same or any other circumstance which might otherwise constitute
a legal or equitable discharge or defense. Without limiting the foregoing, and notwithstanding
anything to the contrary contained elsewhere in this CVR Agreement, in the event that the amount of
Senior Obligations are reduced or diminished for any reason (other than as a result of the payment
in cash or cash equivalents thereof), whether because of the applicability of fraudulent conveyance
or other applicable Laws, or any other invalidity or limitation on the amount of Senior
Obligations, the subordination provisions thereof shall apply to the full amount of Senior
Obligations (without giving effect to any reduction, invalidity or diminution thereof), and the
turnover provisions hereunder shall be fully enforceable with respect to the full amount of Senior
Obligations (without giving effect to any such reduction, invalidity or diminution thereof), even
if the effect thereof is that there will be no (or a limited amount of) Senior Obligations to which
the Junior Obligations are subrogated after the payment in full in cash of any of then remaining
Senior Obligations (without giving effect to any reductions, invalidity or diminution thereof,
except for reductions as a result of payments thereof in cash or cash equivalents).

(b) The Trustee and the Holders agree that they shall not (and hereby waive any right to) take
any action to contest or challenge (or assist or support any other Person in contesting or
challenging), directly or indirectly, whether or not in any proceeding (including in any proceeding
commenced by or against any Person under any provision of Title 11 of the United States Code, as
now and hereinafter in effect, or any successor statute or under any other state or federal
bankruptcy or insolvency Law, assignments for the benefit of creditors, formal or informal
moratoria, compositions, extensions generally with creditors, or proceedings seeking
reorganization, arrangement, or other similar relief), the validity or enforceability of the Senior
Obligations.

 

47

 

(c) If any payment made or in respect to the Senior Obligations must be disgorged or returned
for any reason, the Senior Obligations shall be reinstated hereunder and for all purposes of this
Article 10 (including, without limitation, the turnover provisions hereof) such payment shall be
deemed to have never been made with respect to the Senior Obligations.

Section 10.7 Subrogation. After all Senior Obligations are paid in full in cash or
cash equivalents and until the Junior Obligations are paid in full, Holders will be subrogated to
the rights of holders of Senior Obligations to receive distributions applicable to Senior
Obligations to the extent that distributions otherwise payable to the Holders have been applied to
the payment of Senior Obligations. The Holders by accepting the Securities acknowledge that to the
extent that the Senior Obligations are determined to be unenforceable, or the Senior Obligations
are subordinated to other obligations of the Company, such subrogation rights may be impaired.

Section 10.8 Relative Rights. This Article 10 defines the relative rights of Holders
and holders of Senior Obligations. Nothing in this CVR Agreement will:

(a) impair, as between the Company and Holders, the obligations of the Company under this CVR
Agreement and the Securities; or

(b) affect the relative rights of Holders and creditors of the Company other than their rights
in relation to holders of Senior Obligations.

(c) If the Company fails because of this Article 10 to pay any amounts due in respect of the
Securities on a due date in violation of Section 8.1, the failure is still an Event of Default.

Section 10.9 Subordination May Not Be Impaired by Company. No right of any holder of
Senior Obligations to enforce the subordination of the Junior Obligations may be impaired by any
act or failure to act by the Company or any Holder or by the failure of the Company or any Holder
to comply with this CVR Agreement.

Section 10.10 Distribution or Notice to Representative. Whenever a distribution is to
be made or a notice given to holders of Senior Obligations, the distribution may be made and the
notice given to their representative in accordance with the terms of the instrument or other
agreement governing such Senior Obligations. Upon any payment or distribution of assets of the
Company referred to in this Article 10, the Trustee and the Holders will be entitled to rely upon
any order or decree made by any court of competent jurisdiction or upon any certificate of such
representative or of the liquidating trustee or agent or other Person making any distribution to
the Trustee or to the Holders for the purpose of ascertaining the Persons entitled to participate
in such distribution, the holders of the Senior Obligations and other obligations of the Company,
the amount thereof or payable thereon, the amount or amounts paid or distributed thereon and all
other facts pertinent thereto or to this Article 10.

 

48

 

Section 10.11 Rights of the Trustee. Notwithstanding the provisions of this Article
10 or any other provision of this CVR Agreement, the Trustee will not be charged with knowledge of
the existence of any facts that would prohibit the making of any payment or distribution by the
Trustee, and the Trustee may continue to make payments on the Securities, unless the Trustee has
received at its address for notice specified in Section 1.5 at least five (5) Business Days prior
to the date of such payment written notice of facts that would cause the payment of any Junior
Obligations to violate this Article 10. Only the Company or a representative of Senior Obligations
may give the notice. Nothing in this Article 10 will impair the claims of, or payments to, the
Trustee under or pursuant to Section 4.7 hereof. The Trustee in its individual or any other
capacity may hold Senior Obligations with the same rights it would have if it were not the Trustee.

Section 10.12 Authorization to Effect Subordination. Each Holder, by the Holder’s
acceptance of the Securities, authorizes and directs the Trustee on such Holder’s behalf to take
such action as may be necessary or appropriate to effectuate the subordination as provided in this
Article 10, and appoints the Trustee to act as such Holder’s attorney-in-fact for any and all such
purposes. If the Trustee (or any other Person acting on behalf of and at the
direction of the Majority Holders) does not file a proper proof of claim or proof of debt in
the form required in any proceeding referred to in Section 8.2 hereof at least thirty (30) days
before the expiration of the time to file such claim, the representatives of the Senior Obligations
are hereby authorized to file an appropriate claim for and on behalf of the Holders of the
Securities.

Section 10.13 Amendments. The provisions of this Article 10 are expressly made for
the benefit of the holders from time to time of the Senior Obligations, and may not be amended or
modified without the written consent of the representatives of the holders of all Senior
Obligations.

ARTICLE 11

REDEMPTION OF SECURITIES

Section 11.1 Notice to Trustee. If the Company elects to redeem Securities pursuant
to the optional redemption provisions of Section 11.6 hereof, it shall furnish to the Trustee, at
least forty five (45) days (unless a shorter period shall be agreed to by the Trustee) but not more
than sixty (60) days before a redemption date (but in any event prior to the notice provided
pursuant to Section 11.3 hereof), an Officer’s Certificate (a “Consent and Purchase Offer”)
setting forth (i) the clause of this CVR Agreement pursuant to which the redemption shall occur,
(ii) the redemption date, (iii) the amount of CVRs to be redeemed and (iv) the redemption price.

Section 11.2 Selection of Securities to be Redeemed. If less than all of the
Securities are to be redeemed or purchased in a Consent and Purchase Offer at any time, the Trustee
shall select the Securities to be redeemed or purchased among the Holders in compliance with the
requirements of the principal national securities exchange, if any, on which the Securities are
listed or, if the Securities are not so listed, on a pro rata basis, by lot or in accordance with
any other method the Trustee considers fair and appropriate. In the event of partial redemption by
lot, the particular Securities to be redeemed shall be selected, unless otherwise provided herein,
not less than thirty (30) nor more than sixty (60) days prior to the redemption date by the Trustee
from the outstanding Securities not previously called for redemption. The Trustee shall promptly
notify the Company in writing of the Securities selected for redemption or purchase.

 

49

 

Section 11.3 Notice of Redemption. At least thirty (30) days but not more than sixty
(60) days before a redemption date, the Company shall mail or cause to be mailed, by first class
mail, a notice of redemption to each Holder whose Securities are to be redeemed at its registered
address. The notice (the “Call Notice”) shall identify the amount of Securities to be
redeemed and shall state:

(a) the redemption date;

(b) the redemption price;

(c) the name and address of the paying agent;

(d) that Securities called for redemption must be surrendered to the Paying Agent to collect
the redemption price;

(e) that, unless the Company defaults in making such redemption payment, all right title and
interest in and to the Securities and any Net Sales Payment, Milestone Payment or any other amounts
due under this CVR Agreement, if any, on Securities called for redemption ceases to accrue on and
after the redemption date;

(f) the clause of this CVR Agreement pursuant to which the Securities called for redemption
are being redeemed; and

(g) that no representation is made as to the correctness or accuracy of the CUSIP and ISIN
number, if any, listed in such notice or printed on the Securities.

At the Company’s request, the Trustee shall give the notice of redemption in the Company’s name and
at its expense; provided, however, that the Company shall have delivered to the Trustee at least
forty five (45) days (unless a shorter period shall be agreed to by the Trustee) but not more than
sixty (60) days prior to the redemption date, an Officer’s Certificate requesting that the Trustee
give such notice and setting forth the information to be stated in such notice as provided in the
preceding paragraph.

Section 11.4 Effect of Notice of Redemption. Once notice of redemption is mailed in
accordance with Section 11.3 hereof, Securities called for redemption shall become irrevocably due
and payable on the redemption date at the redemption price. A notice of redemption shall be deemed
to be given when mailed, whether or not the Holder receives the notice. In any event, failure to
give such notice, or any defect in such notice, shall not affect the validity of the proceedings
for the redemption of the Securities held by Holders to whom such notice was properly given.

 

50

 

Section 11.5 Deposit of Redemption Price. On or one (1) Business Day prior to the
redemption date, the Company shall deposit with the Trustee or with the paying agent (if different
from the Trustee) money sufficient to pay the redemption price of all Securities to be redeemed on
that date. The Trustee or the paying agent shall promptly return to the Company any money
deposited with the Trustee or the paying agent by the Company in excess of the amounts necessary to
pay the redemption price of all Securities to be redeemed.

If the Company complies with the provisions of the preceding paragraph, on and after the redemption
or purchase date, as applicable, all right title and interest of a Holder to any Net Sales Payment
or Milestone Payment, if any, shall cease to accrue on the Securities called for redemption or
subject to purchase. If any Security called for redemption or subject to purchase shall not be so
paid upon surrender for redemption or purchase because of the failure of the Company to comply with
the preceding paragraph, interest shall be paid on the unpaid redemption price from the redemption
date or Purchase Date, as applicable, until such redemption price is paid at the Shortfall Interest
Rate.

Section 11.6 Optional Redemption by the Company. The Company may, at any time on and
after the Redemption Eligibility Date, redeem all (but not less than all) of the outstanding
Securities at a cash redemption price equal to the average price paid per Security for
all Securities previously purchased by the Company calculated as of the Business Day
immediately prior to the date of the Call Notice mailed by the Company in accordance with Section
11.3 hereof.

 

51

 

IN WITNESS WHEREOF, the Parties hereto have caused this CVR Agreement to be duly executed, all
as of the day and year first above written.

	 	 	 	 	 
	 	CELGENE CORPORATION

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	[•],
as the Trustee

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

 

52

 

ANNEX A

CELGENE CORPORATION

					
	 	 	 	 	 
	No.
	 	Certificate for
	 	Contingent Value Rights

This certifies that
 _____, or registered assigns (the “Holder”), is the
registered holder of the number of Contingent Value Rights (“CVRs” or “Securities”)
set forth above. Each CVR entitles the Holder, subject to the provisions contained herein and in
the CVR Agreement referred to on the reverse hereof, to payments from Celgene Corporation, a
Delaware corporation (the “Company”), in an amounts and in the forms determined pursuant to
the provisions set forth on the reverse hereof and as more fully described in the CVR Agreement
referred to on the reverse hereof. Such payments shall be made on a Payment Date, as defined in
the CVR Agreement referred to on the reverse hereof.

Payment of any amounts pursuant to this CVR Certificate shall be made only to the registered
Holder (as defined in the CVR Agreement) of this CVR Certificate. Such payment shall be made in
the Borough of Manhattan, The City of New York, or at any other office or agency maintained by the
Company for such purpose, in such coin or currency of the United States of America as at the time
is legal tender for the payment of public and private debts; provided, however, the Company may pay
such amounts by wire transfer or check payable in such money. [TRUSTEE] has been initially
appointed as Paying Agent at its office or agency in the Borough of Manhattan, The City of New
York.

Reference is hereby made to the further provisions of this CVR Certificate set forth on the
reverse hereof, which further provisions shall for all purposes have the same effect as if set
forth at this place.

Unless the certificate of authentication hereon has been duly executed by the Trustee referred
to on the reverse hereof by manual signature, this CVR Certificate shall not be entitled to any
benefit under the CVR Agreement, or be valid or obligatory for any purpose.

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed.

	 	 	 	 	 	 	 
	Dated:

	 	[•]

 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

Name:
	 	 
	 

	 	 	 	Title:	 	 
	 
	 	 	 	 	 	 
	Attest:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

Authorized Signature

	 	 	 	 	 	 

 

A-1

 

[Form of Reverse of CVR Certificate]

1. This CVR Certificate is issued under and in accordance with the Contingent Value Rights
Agreement, dated as of [•], 2010 (the “CVR Agreement”), between the Company and [•], a
national banking association, as trustee (the “Trustee,” which term includes any successor
Trustee under the CVR Agreement), and is subject to the terms and provisions contained in the CVR
Agreement, to all of which terms and provisions the Holder of this CVR Certificate consents by
acceptance hereof. The CVR Agreement is hereby incorporated herein by reference and made a part
hereof. Reference is hereby made to the CVR Agreement for a full statement of the respective
rights, limitations of rights, duties, obligations and immunities thereunder of the Company, the
Trustee and the Holders of the CVRs. All capitalized terms used in this CVR Certificate without
definition shall have the respective meanings ascribed to them in the CVR Agreement. Copies of the
CVR Agreement can be obtained by contacting the Trustee.

2. On each Net Sales Payment Date, the Company shall pay to the Holder hereof, for each CVR
represented hereby, a pro rata portion of the Net Sales Payment, if any, with respect to the Net
Sales Measuring Period ended immediately prior to such Net Sales Payment Date.

3. In the event of any conflict between this CVR Certificate and the CVR Agreement, the CVR
Agreement shall govern and prevail.

4. Subject to the terms and conditions of the CVR Agreement, on each Milestone Payment Date
(or, in any such case, if such day is not a Business Day, without accruing any interest, on the
next succeeding Business Day), the Company shall pay to the Holder hereof, for each CVR represented
hereby, a pro rata portion of the applicable Milestone Payment with respect to the occurrence of a
Milestone.

5. Each CVR Payment, if any, and interest thereon, if any, shall be payable by the Company in
such coin or currency of the United States of America as at the time is legal tender for the
payment of public and private debts; provided, however, the Company may pay such amounts by its
check or wire transfer payable in such money. [TRUSTEE] has been initially appointed as Paying
Agent at its office or agency in the Borough of Manhattan, The City of New York.

6. If an Event of Default occurs and is continuing, either the Trustee may or the Majority
Holders, by notice to the Company and to the Trustee shall bring suit in accordance with the terms
and conditions of the CVR Agreement to protect the rights of the Holders, including to obtain
payment of all amounts then due and payable, with interest at the Default Interest Rate from the
date of the Event of Default through the date payment is made or duly provided for.

7. No reference herein to the CVR Agreement and no provision of this CVR Certificate or of the
CVR Agreement shall alter or impair the obligation of the Company, which is absolute and
unconditional, to pay any amounts determined pursuant to the terms hereof and of the CVR Agreement
at the times, place and amount, and in the manner, herein prescribed.

 

A-2

 

8. Each CVR Payment or any other right, claim or payment of any kind under this CVR
Certificate, if any, shall be subordinated in right of payment, as set forth in Article 10 of the
CVR Agreement, to the prior payment in full in cash or cash equivalents of all Senior Obligations
whether outstanding on the date of the CVR Agreement or thereafter incurred.

9. As provided in the CVR Agreement and subject to certain limitations therein set forth, the
transfer of the CVRs represented by this CVR Certificate is registrable on the Security Register,
upon surrender of this CVR Certificate for registration of transfer at the office or agency of the
Company maintained for such purpose in the Borough of Manhattan, The City of New York, duly
endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company
and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in
writing, and thereupon one or more new CVR Certificates, for the same amount of CVRs, will be
issued to the designated transferee or transferees. The Company hereby initially designates the
office of [TRUSTEE] at [•] as the office for registration of transfer of this CVR Certificate.

10. As provided in the CVR Agreement and subject to certain limitations therein set forth,
this CVR Certificate is exchangeable for one or more CVR Certificates representing the same number
of CVRs as represented by this CVR Certificate as requested by the Holder surrendering the same.

11. No service charge will be made for any registration of transfer or exchange of CVRs, but
the Company may require payment of a sum sufficient to cover all documentary, stamp or similar
issue or transfer taxes or other governmental charges payable in connection with any registration
of transfer or exchange.

12. Prior to the time of due presentment of this CVR Certificate for registration of transfer,
the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose
name this CVR Certificate is registered as the owner hereof for all purposes, and neither the
Company, the Trustee nor any agent shall be affected by notice to the contrary.

13. Neither the Company nor the Trustee has any duty or obligation to the holder of this CVR
Certificate, except as expressly set forth herein or in the CVR Agreement.

14. Redemption.

(a) Notice to Trustee. If the Company elects to redeem Securities pursuant to the
optional redemption provisions of Section 11.6 of the CVR Agreement, it shall furnish to the
Trustee, at least forty five (45) days (unless a shorter period shall be agreed to by the Trustee)
but not more than sixty (60) days before a redemption date (but in any event prior to the notice
provided pursuant to Section 11.3 of the CVR Agreement), an Officer’s Certificate (a “Consent
and Purchase Offer”) setting forth (i) the clause of the CVR Agreement pursuant to which the
redemption shall occur, (ii) the redemption date, (iii) the amount of CVRs to be redeemed and (iv)
the redemption price.

 

A-3

 

(b) Selection of Securities to be Redeemed. If less than all of the Securities are to
be redeemed or purchased in a Consent and Purchase Offer at any time, the Trustee shall select the
Securities to be redeemed or purchased among the Holders in compliance with the requirements of the
principal national securities exchange, if any, on which the Securities are listed or, if the
Securities are not so listed, on a pro rata basis, by lot or in accordance with any other method
the Trustee considers fair and appropriate. In the event of partial redemption by lot, the
particular Securities to be redeemed shall be selected, unless otherwise provided herein, not less
than thirty (30) nor more than sixty (60) days prior to the redemption date by the Trustee from the
outstanding Securities not previously called for redemption. The Trustee shall promptly notify the
Company in writing of the Securities selected for redemption or purchase.

(c) Notice of Redemption. At least thirty (30) days but not more than sixty (60) days
before a redemption date, the Company shall mail or cause to be mailed, by first class mail, a
notice of redemption to each Holder whose Securities are to be redeemed at its registered address.
The notice shall identify the amount of Securities to be redeemed and shall state:

(i) the redemption date;

(ii) the redemption price;

(iii) the name and address of the paying agent;

(iv) that Securities called for redemption must be surrendered to the Paying Agent to
collect the redemption price;

(v) that, unless the Company defaults in making such redemption payment, all right
title and interest in and to the Securities and any Net Sales Payment, Milestone Payment or
any other amounts due under the CVR Agreement, if any, on Securities called for redemption
ceases to accrue on and after the redemption date;

(vi) the clause of the CVR Agreement pursuant to which the Securities called for
redemption are being redeemed; and

(vii) that no representation is made as to the correctness or accuracy of the CUSIP and
ISIN number, if any, listed in such notice or printed on the Securities.

At the Company’s request, the Trustee shall give the notice of redemption in the Company’s name and
at its expense; provided, however, that the Company shall have delivered to the Trustee at least
forty five (45) days (unless a shorter period shall be agreed to by the Trustee) but not more than
sixty (60) days prior to the redemption date, an Officer’s Certificate requesting that the Trustee
give such notice and setting forth the information to be stated in such notice as provided in the
preceding paragraph.

 

A-4

 

(d) Effect of Notice of Redemption. Once notice of redemption is mailed in accordance
with Section 11.3 of the CVR Agreement, Securities called for redemption shall become irrevocably
due and payable on the redemption date at the redemption price. A notice of redemption shall be
deemed to be given when mailed, whether or not the Holder receives the notice. In any event,
failure to give such notice, or any defect in such notice, shall not affect the validity of the
proceedings for the redemption of the Securities held by Holders to whom such notice was properly
given.

(e) Deposit of Redemption Price. On or one (1) Business Day prior to the redemption
date, the Company shall deposit with the Trustee or with the paying agent (if different from the
Trustee) money sufficient to pay the redemption price of all Securities to be redeemed on that
date. The Trustee or the paying agent shall promptly return to the Company any money deposited
with the Trustee or the paying agent by the Company in excess of the amounts necessary to pay the
redemption price of all Securities to be redeemed.

If the Company complies with the provisions of the preceding paragraph, on and after the redemption
or purchase date, as applicable, all right title and interest of a Holder to any Net Sales Payment
or Milestone Payment, if any, shall cease to accrue on the Securities called for redemption or
subject to purchase. If any Security called for redemption or subject to purchase shall not be so
paid upon surrender for redemption or purchase because of the failure of the Company to comply with
the preceding paragraph, interest shall be paid on the unpaid redemption price from the redemption
date or Purchase Date, as applicable, until such redemption price is paid at the Shortfall Interest
Rate.

(f) Optional Redemption by the Company. The Company may, at any time on and after the
Redemption Eligibility Date, redeem all (but not less than all) of the outstanding Securities at a
cash redemption price equal to the average price paid per Security for all Securities previously
purchased by the Company calculated as of the Business Day immediately prior to the date of the
Call Notice mailed by the Company in accordance with Section 11.3 of the CVR Agreement.

 

A-5

 

TRUSTEE’S CERTIFICATE OF AUTHENTICATION

This is one of the CVR Certificates referred to in the within-mentioned CVR Agreement.

	 	 	 	 	 	 
	 	 	[•],
as the Trustee	 
	 
	 	 	 	 	 
	Dated:                                         

	 	By:	 	 	 
	 

	 	 	 	 	 
	 

	 	 	 	Authorized Signatory	 

 

A-6Exhibit 10.2

Exhibit 10.2

VOTING AGREEMENT

This VOTING AGREEMENT (this “Agreement”) is entered into as of June 30, 2010, by and
among Celgene Corporation, a Delaware corporation (“Parent”), Artistry Acquisition Corp., a
Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), and the Persons whose
names are set forth on the signature pages hereto under the caption “Stockholders” (each
individually a “Stockholder” and, collectively, the “Stockholders”).

W I T N E S S E T H:

WHEREAS, as of the date of this Agreement, each Stockholder owns the number of shares of
Common Stock, par value $.001 per share (the “Company Stock”), of Abraxis BioScience, Inc.,
a Delaware corporation (the “Company”), set forth opposite such Stockholder’s name on
Schedule A attached hereto;

WHEREAS, concurrently herewith, Parent, Sub and the Company are entering into an Agreement and
Plan of Merger, dated as of this date (the “Merger Agreement”), pursuant to which Sub will
merge with and into the Company and the Company will survive as a wholly-owned subsidiary of Parent
(the “Merger”), and each share of Company Stock (other than Excluded Company Shares) will
be converted into the right to receive the Merger Consideration, in accordance with the terms of,
and subject to the conditions set forth in, the Merger Agreement; and

WHEREAS, as a condition to the willingness of Parent and Sub to enter into the Merger
Agreement, and as an inducement and in consideration therefor, Parent and Sub have required that
the Stockholders agree, and the Stockholders have agreed, to enter into this Agreement.

NOW, THEREFORE, in consideration of the foregoing and the mutual premises, representations,
warranties, covenants and agreements contained in this Agreement, the parties, intending to be
legally bound, hereby agree as follows:

ARTICLE I

DEFINITIONS

SECTION 1.1 Defined Terms. For purposes of this Agreement, terms used in this
Agreement that are defined in the Merger Agreement but not in this Agreement shall have the
respective meanings ascribed to them in the Merger Agreement.

SECTION 1.2 Other Definitions. For purposes of this Agreement:

(a) “Company Options” means options to acquire Company Stock granted to a Stockholder
by the Company and held by a Stockholder as of the date of this Agreement as set forth on
Schedule A.

 

 

 

(b) “Company RSUs” means restricted stock units with respect to Company Stock granted
to a stockholder by the Company and held by a Stockholder as of the date of this Agreement as set
forth on Schedule A.

(c) “Immediate Family” means lineal descendants (whether by blood or marriage),
ancestral forebears, current and former spouses, and persons related by blood, adoption or marriage
to any of the foregoing.

(d) “New Shares” means any shares of Company Stock (other than Owned Shares) acquired
by a Stockholder at any time during the Voting Period.

(e) “Option Shares” means any shares of Company Stock issued or issuable upon exercise
of Company Options.

(f) “Owned Shares” means all of the shares of Company Stock owned by such Stockholder
as of the date of this Agreement as set forth on Schedule A.

(g) “Permitted Transferee” means PSS and any PSS Entity or any charitable foundation
or organization, in each case only if such parties agree to be bound by the terms of this
Agreement.

(h) “PSS” means Dr. Patrick Soon-Shiong.

(i) “PSS Entity” means any trust for the benefit of PSS or any members of PSS’
Immediate Family and any other entity in which PSS or any members of PSS’ Immediate Family
separately or collectively hold, directly or indirectly, a majority of the outstanding equity
interests.

(j) “Representative” means, with respect to any particular Person, the officers,
directors, employees, trustees, investment bankers, attorneys and other advisors or representatives
of such Person.

(k) “RSU Shares” means any shares of Company Stock issued or issuable upon vesting of
Company RSUs.

(l) “Transfer” means sell, transfer, tender, assign, pledge, encumber or otherwise
dispose.

(m) “Voting Period” means the period from and including the date of this Agreement
through and including the earliest to occur of (i) the Effective Time, and (ii) the termination of
the Merger Agreement in accordance with its terms.

 

-2-

 

ARTICLE II

VOTING AGREEMENT AND IRREVOCABLE PROXY

SECTION 2.1 Agreement to Vote.

(a) Each Stockholder hereby agrees that, during the Voting Period, such Stockholder shall vote
or execute consents, as applicable, with respect to the Owned Shares and any New Shares owned by
such Stockholder as of the applicable record date (or cause to be voted or a consent to be executed
with respect to the Owned Shares or any New Shares owned by such Stockholder as of the applicable
record date) in favor of the approval and adoption of the Merger Agreement and the transactions
contemplated by the Merger Agreement, at any meeting (or any adjournment or postponement thereof)
of, or in connection with any proposed action by written consent of, the holders of Company Stock
at or in connection with which any of the holders vote or execute consents with respect to any of
the foregoing matters.

(b) Subject to Section 3.2 hereof, each Stockholder hereby agrees that, during the Voting
Period, such Stockholder shall vote or execute consents, as applicable, with respect to the Owned
Shares and any New Shares owned by such Stockholder as of the applicable record date (or cause to
be voted or a consent to be executed with respect to the Owned Shares and any New Shares owned by
such Stockholder as of the applicable record date) against each of the matters set forth in clauses
(i), (ii), (iii) and (iv) below at any meeting (or any adjournment or postponement thereof) of, or
in connection with any proposed action by written consent of, the holders of Company Stock at or in
connection with which any of the holders vote or execute consents with respect to any of the
following matters:

(i) any merger agreement or merger (other than the Merger Agreement, the Merger or any
business combination or transaction with Parent or any of its affiliates), consolidation,
combination, reorganization, recapitalization, dissolution, liquidation or winding up of or
by the Company or any other business combination or extraordinary corporate transaction
involving the Company or any of its Subsidiaries, or any sale, lease or transfer of a
material amount of assets of the Company or any of its Subsidiaries;

(ii) any amendment of the Company’s certificate of incorporation, as amended to date,
unless such amendment is consented to by Parent;

(iii) any action, proposal, transaction or agreement that would reasonably be expected
to result in a breach in any respect of any covenant, representation or warranty or any
other obligation or agreement of the Company contained in the Merger Agreement or of such
Stockholder contained in this Agreement; and

(iv) any action, proposal, transaction or agreement involving the Company or any of
its Subsidiaries that would reasonably be expected to prevent,
impede, frustrate, interfere with, delay, postpone or adversely affect the Merger and
the other transactions contemplated by the Merger Agreement.

 

-3-

 

(c) Any vote required to be cast or consent required to be executed pursuant to this Section
2.1 shall be cast or executed in accordance with the applicable procedures relating thereto so as
to ensure that it is duly counted for purposes of determining that a quorum is present (if
applicable) and for purposes of recording the results of that vote or consent. Nothing contained
in this Section 2.1 shall require any Stockholder to vote or execute any consent with respect to
any Option Shares or RSU Shares not issued to the Stockholder prior to the applicable record date
for that vote or consent.

SECTION 2.2 Grant of Irrevocable Proxy. Each Stockholder hereby irrevocably appoints
Parent and any designee of Parent, and each of them individually, as such Stockholder’s proxy and
attorney-in-fact, with full power of substitution and resubstitution, to vote or execute consents
during the Voting Period, with respect to the Owned Shares and any New Shares owned by such
Stockholder as of the applicable record date, in each case solely to the extent and in the manner
specified in Section 2.1. This proxy is given to secure the performance of the duties of such
Stockholder under this Agreement, and its existence will not be deemed to relieve such Stockholder
of its obligations under Section 2.1. Other than as described in this Section 2.2
and other than the granting of proxies to vote Owned Shares or New Shares with respect to the
election of directors and ratification of the appointment of the Company’s auditors at the
Company’s annual meeting of Stockholders, in accordance with the recommendation of the Board of
Directors of the Company, such Stockholder shall not directly or indirectly grant any Person any
proxy (revocable or irrevocable), power of attorney or other authorization with respect to any of
such Stockholder’s Owned Shares or New Shares. For Owned Shares or New Shares as to which the
Stockholder is the beneficial but not the record owner, such Stockholder will cause any record
owner of such Owned Shares or New Shares to grant to Parent a proxy to the same effect as that
contained in this Section 2.2.

SECTION 2.3 Nature of Irrevocable Proxy. The proxy and power of attorney granted
pursuant to Section 2.2 by each Stockholder shall be irrevocable during the Voting Period, shall be
deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall
revoke any and all prior proxies granted by such Stockholder with regard to such Stockholder’s
Owned Shares or any New Shares acquired by such Stockholder, and such Stockholder acknowledges that
the proxy constitutes an inducement for Parent and Sub to enter into the Merger Agreement. The
power of attorney granted by each Stockholder is a durable power of attorney and shall survive the
bankruptcy, dissolution, death or incapacity of such Stockholder. The proxy and power of attorney
granted hereunder shall terminate only upon the expiration of the Voting Period.

 

-4-

 

ARTICLE III

COVENANTS

SECTION 3.1 Voting Period Restrictions. Each Stockholder agrees that such Stockholder
shall not, during the Voting Period, (i) Transfer any or all of such Stockholder’s Owned Shares or
New Shares, or any interest therein, or enter into any agreement with respect to the Transfer of
any or all of such Stockholder’s Owned Shares or New Shares, or any interest therein, or (ii)
except pursuant to the terms of this Agreement, grant any proxies or powers of attorney, deposit
any Owned Shares or New Shares into a voting trust or enter into a voting agreement with respect to
any Owned Shares or New Shares; provided that the foregoing shall not prevent (a) the
Transfer of Owned Shares or New Shares upon the death of such Stockholder pursuant to the terms of
any trust or will of such Stockholder or by the laws of intestate succession, but only if, and any
such Transfer shall be void unless, the transferee executes and delivers to Parent an agreement to
be bound by the terms of this Agreement to the same extent as such Stockholder, (b) the Transfer of
Owned Shares or New Shares to a Permitted Transferee, (c) the Transfer of Owned Shares or New
Shares solely in connection with the payment of the exercise price and/or the satisfaction of any
tax withholding obligation arising from the exercise of any Company Option or the vesting of any
Company RSU, (d) the conversion of any Owned Shares and New Shares into the right to receive the
Merger Consideration pursuant to the Merger in accordance with the terms of the Merger Agreement,
or (e) the granting of proxies to vote Owned Shares or New Shares with respect to the election of
directors and ratification of the appointment of the Company’s auditors at the Company’s annual
meeting of Stockholders, in accordance with the recommendation of the Board of Directors of the
Company.

SECTION 3.2 No Shop Obligations of Each Stockholder. Each Stockholder agrees that such
Stockholder shall not, and that such Stockholder shall use its reasonable best efforts to cause the
Representatives of such Stockholder to not, directly or indirectly, (i) solicit, initiate, or
knowingly encourage the making, submission or announcement of any inquiry regarding, or any
proposal or offer which would reasonably be expected to lead to, an Acquisition Proposal, (ii)
enter into, participate, continue or otherwise engage in discussions or negotiations with, or
provide any non-public information to any Person (other than Parent, Sub and their Representatives)
with respect to any inquiries regarding, or the making, submission or announcement of, an
Acquisition Proposal, or (iii) enter into or approve any letter of intent, agreement in principle,
option agreement, share purchase agreement, acquisition agreement or similar agreement relating to
an Acquisition Proposal; provided, however, that each Stockholder may, and may
authorize and permit any Representative of such Stockholder to, provide non-public information to,
and participate in discussions or negotiations, with any Person if at such time such Stockholder
has been notified by the Company that the Board of Directors of the Company is permitted to provide
non-public information to, or engage in discussions or negotiations with, such Person in accordance
with the Merger Agreement. The Stockholder shall immediately cease and cause to be terminated any
ongoing solicitation, discussion or negotiation with any Person conducted prior to the date of this
Agreement by the Stockholder or any of its Representatives with respect to any actual or potential
Acquisition Proposal. A Stockholder shall notify Parent orally and in writing promptly
(and in any event within 24 hours) after receipt of any Acquisition Proposal or any request
for information or inquiry which could reasonably be expected to lead to an Acquisition Proposal.
The written notice shall include the identity of the Person making such Acquisition Proposal,
request or inquiry, the material terms of the Acquisition Proposal, request or inquiry (including
any material written amendments or modifications, or any proposed material written amendments or
modifications, thereto), and the Stockholder shall keep Parent reasonably informed on a current
basis of any material changes with respect to such Acquisition Proposal, request or inquiry.

 

-5-

 

SECTION 3.3 General Covenants. Each Stockholder agrees that such Stockholder shall
not:

(a) enter into any agreement, commitment, letter of intent, agreement in principle, or
understanding with any Person or take any other action that violates or conflicts with or would
reasonably be expected to violate or conflict with, or result in or give rise to a violation of or
conflict with, such Stockholder’s covenants and obligations under this Agreement or make any of its
representations and warranties contained herein untrue or incorrect; or

(b) take any action that could restrict or otherwise affect such Stockholder’s legal power,
authority and right to comply with and perform such Stockholder’s covenants and obligations under
this Agreement.

SECTION 3.4 Stockholders’ Capacity. Parent and Sub acknowledge that no Stockholder is
making any agreement or understanding herein in such Stockholder’s capacity as a director or
officer of the Company and that each Stockholder is executing this agreement solely in such
Stockholder’s capacity as the owner of Company Stock and nothing herein shall limit or affect any
actions taken by such Stockholder in such Stockholder’s capacity as a director or officer of the
Company.

SECTION 3.5 Letter of Transmittal and Delivery of Merger Consideration. Parent agrees
to provide the Stockholders a copy of the letter of transmittal referenced in Section 2.2 of the
Merger Agreement a reasonable time period prior to the anticipated Closing Date to allow the
Stockholders to complete the letter of transmittal and provide such letter of transmittal to the
Paying Agent prior to or on the Closing Date. Parent agrees to use reasonable best efforts to
cause the Paying Agent to deliver by wire transfer of immediately available funds the Merger
Consideration to which the Stockholders are entitled under the terms of the Merger Agreement on the
same date as the Closing Date.

 

-6-

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS

Each Stockholder hereby represents and warrants to Parent and Sub as follows:

SECTION 4.1 Authorization. Such Stockholder has all power and authority (or legal
capacity in the case of an individual) to execute and deliver this Agreement and to perform its
obligations hereunder. This Agreement has been duly and validly
authorized, executed and delivered by such Stockholder and, assuming it has been duly and
validly authorized, executed and delivered by Parent and Sub, constitutes a legal, valid and
binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its
terms, except to the extent that enforceability may be limited by (i) applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws now or
hereafter in effect relating to creditor’s rights generally, and (ii) general principles of equity.

SECTION 4.2 Ownership of Shares. As of the date hereof, all Owned Shares, Company
Options and Company RSUs owned by such Stockholder are listed on Schedule A attached
hereto. Such Stockholder (a) is the sole beneficial owner of all of the Owned Shares, Company
Options and Company RSUs listed opposite such Stockholder’s name on Schedule A hereto free
and clear of any Liens, voting agreements or commitments of every kind that would reasonably be
expected to violate or conflict with, or result in or give rise to a violation of or conflict with,
or adversely affect the exercise or fulfillment of, such Stockholder’s covenants and obligations
under this Agreement, and (b) has the sole power to vote (or cause to be voted or consents to be
executed) and to dispose of (or cause to be disposed of) such Owned Shares without restriction, and
no proxies through and including the date hereof given in respect of any or all of such
Stockholder’s Owned Shares, Company Options or Company RSUs are irrevocable and any such proxies
have been revoked.

SECTION 4.3 No Conflicts. Except for a filing of an amendment to a Schedule 13D and a
filing of a Form 4 as required by the Exchange Act, (i) no filing with any Governmental Entity, and
no authorization, consent or approval of any other Person is necessary for the execution of this
Agreement by such Stockholder or the performance by such Stockholder of such Stockholder’s
obligations hereunder and (ii) none of the execution and delivery of this Agreement by such
Stockholder, or the performance by such Stockholder of such Stockholder’s obligations hereunder
shall (A) result in, give rise to or constitute a violation or breach of or a default (or any event
which with notice or lapse of time or both would become a violation, breach or default) under, or
give to others any rights of termination, amendment, acceleration or cancellation of, or result in
the creation of a Lien on, any of the Owned Shares pursuant to any of the terms of any
understanding, agreement, or other instrument or obligation to which such Stockholder is a party or
by which such Stockholder or any of such Stockholder’s Owned Shares are bound, or (B) violate any
applicable law, rule, regulation, order, judgment, or decree applicable to such Stockholder, except
for any of the foregoing as would not reasonably be expected to impair such Stockholder’s ability
to perform such Stockholder’s obligations under this Agreement in any material respect.

 

-7-

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF PARENT AND SUB

Each of Parent and Sub hereby represent and warrant to the Stockholders as follows:

SECTION 5.1 Authorization. Such party has all power and authority to execute and
deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly and
validly authorized, executed and delivered by such party and, assuming it has been duly and validly
authorized, executed and delivered by the Stockholders, constitutes a legal, valid and binding
obligation of such party, enforceable against it in accordance with the terms of this Agreement.

SECTION 5.2 No Conflicts. The execution and delivery of this Agreement by such party
does not and the performance of this Agreement by such party will not (i) conflict with, result in
any violation of, require any consent under or constitute a default (whether with notice or lapse
of time or both) under any mortgage, bond, indenture, agreement, instrument or obligation to which
it is a party or by which it or any of its properties is bound; (ii) violate any judgment, order,
injunction, decree or award of any court, administrative agency or other Governmental Entity that
is binding on such party or any of its properties; or (iii) constitute a violation by such party of
any law, regulation, rule or ordinance applicable to such party, in each case, except for any
violation, conflict or consent as would not reasonably be expected to materially impair the ability
of such party to perform its obligations under this Agreement.

ARTICLE VI

TERMINATION

This Agreement shall terminate upon the earliest to occur of (i) the Effective Time, (ii) any
material amendment to the Merger Agreement that is adverse to the Stockholders that has not been
approved by the Stockholders (it being understood that any decrease in or change in form of the
Merger Consideration shall constitute a material amendment to the Merger Agreement that is adverse
to the Stockholders), and (iii) the termination of the Merger Agreement in accordance with its
terms. Upon the termination of this Agreement, neither Parent, Sub nor the Stockholders shall have
any rights or obligations hereunder and this Agreement shall become null and void and have no
effect; provided, that, with respect to termination pursuant to clause (i) above, Sections
7.1, 7.3 and 7.5 through 7.12 shall survive such termination. Notwithstanding the foregoing,
termination of this Agreement shall not prevent any party from seeking any remedies (at law or in
equity) against any other party for that party’s breach of any of the terms of this Agreement prior
to the date of termination.

ARTICLE VII

MISCELLANEOUS

SECTION 7.1 Publication. Each Stockholder hereby permits Parent, Sub and/or the
Company to publish and disclose in press releases, Schedule 13D filings, and the Proxy
Statement/Prospectus (including all documents and schedules filed with the SEC) and any other
disclosures or filings required under the Merger Agreement or by applicable Law such Stockholder’s
identity and ownership of shares of the Company Stock, the nature of such Stockholder’s
commitments, arrangements and understandings pursuant to this Agreement and/or the text of this
Agreement.

 

-8-

 

SECTION 7.2 Waiver of Appraisal Rights and Actions. Each Stockholder hereby (i)
waives any rights of appraisal or rights to dissent from the Merger or the adoption of the Merger
Agreement that such Stockholder may have under applicable law and shall not permit any such rights
of appraisal or rights of dissent to be exercised with respect to such Stockholder’s Owned Shares,
any New Shares, any Option Shares or any RSU Shares and (ii) agrees not to commence or participate
in, and to take all actions necessary to opt out of any class in any class action with respect to,
any claim, derivative or otherwise, against Parent, Sub, the Company or any of their respective
successors relating to the negotiation, execution or delivery of this Agreement or the Merger
Agreement or the consummation of the Merger, including any claim alleging a breach of any fiduciary
duty of the Board of Directors of the Company in connection with the Merger Agreement or the
transactions contemplated thereby.

SECTION 7.3 Amendments, Waivers, etc. This Agreement may be amended by the parties at
any time. This Agreement may not be amended except by an instrument in writing signed on behalf of
each of the parties. Except as provided in this Agreement, no action taken pursuant to this
Agreement, including any investigation by or on behalf of any party, shall be deemed to constitute
a waiver by the party taking the action of compliance with any representations, warranties,
covenants or agreements contained in this Agreement. The waiver by any party of a breach of any
provision hereunder shall not operate or be construed as a waiver of any prior or subsequent breach
of the same or any other provision hereunder.

SECTION 7.4 Enforcement of Agreement; Specific Performance. The Stockholders agree
and acknowledge that Parent and Sub would suffer irreparable damage in the event that any of the
obligations of the Stockholders in this Agreement were not performed in accordance with its
specific terms or if the Agreement was otherwise breached by the Stockholders. It is accordingly
agreed by the Stockholders that Parent shall be entitled to an injunction or injunctions to prevent
breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement,
this being in addition to any other remedy to which Parent may be entitled at law or in equity.

SECTION 7.5 Notices. Except for notices that are specifically required to be
delivered orally, all notices, requests, claims, demands and other communications hereunder shall
be in writing and shall be deemed given (a) on the date of delivery, if delivered in person or by
facsimile or e-mail (upon confirmation of receipt), (b) on the first Business Day following the
date of dispatch, if delivered by a recognized overnight courier service (upon proof of delivery)
or (c) on the fifth Business Day following the date of mailing, if delivered by registered or
certified mail, postage prepaid, return receipt requested, addressed as follows:

(a) If to the Parent or Sub, addressed to it at:

Celgene Corporation

86 Morris Avenue

Summit, New Jersey 07901

Tel: 908.673.9000

Fax: 908.673.2769

	 	 	 	 	 
	 

	 	Attention:
	 	George Golumbeski, Senior Vice President Business
Development 
ggolumbeski@celgene.com

 

-9-

 

with copies to:

Celgene Corporation

86 Morris Avenue

Summit, New Jersey 07901

Tel: 908.673.9000

Fax: 908.673.2771

	 	 	 	 	 
	 

	 	Attention:
	 	Thomas Perone, Corporate Counsel
	 

	 	 	 	tperone@celgene.com

and a copy (which shall not constitute notice) to:

Jones Day

3161 Michelson Drive

Suite 800

Irvine, CA 92612

Tel: 949.851.3939

Fax: 949.553.7539

	 	 	 	 	 
	 

	 	Attention:
	 	Jonn R. Beeson, Esq.
	 

	 	 	 	jbeeson@jonesday.com
	 

	 	 	 	Kevin Espinola, Esq.
	 

	 	 	 	kbespinola@jonesday.com

(b) If to the Stockholders, addressed to them at:

Abraxis BioScience Inc.

11755 Wilshire Blvd., 20th Floor

Los Angeles, CA 90025

Tel: 310.883.1300

Fax: 310.998.8553

	 	 	 	 	 
	 

	 	Attention:
	 	Dr. Patrick Soon-Shiong, Executive
Chairman

pss@abraxisbio.com

with copies to:

Abraxis BioScience Inc.

11755 Wilshire Blvd., 20th Floor

Los Angeles, CA 90025

Tel: 310.883.1300

Fax: 310.998.8553

	 	 	 	 	 
	 

	 	Attention:
	 	Charles Kim, General Counsel
	 

	 	 	 	CKim@abraxisbio.com

 

-10-

 

and a copy (which shall not constitute notice) to:

Fried, Frank, Harris, Shriver & Jacobson LLP

One New York Plaza

New York, New York 10004

Tel: 212.859.8000

Fax: 212.859.4000

	 	 	 	 	 
	 

	 	Attention:
	 	Philip Richter, Esq.
	 

	 	 	 	philip.richter@friedfrank.com
	 

	 	 	 	Brian Mangino, Esq.
	 

	 	 	 	brian.mangino@friedfrank.com

or to that other address as any party shall specify by written notice so given, and notice shall be
deemed to have been delivered as of the date so telecommunicated or personally delivered.

SECTION 7.6 Headings; Titles. Headings and titles of the Articles and Sections of
this Agreement are for the convenience of the parties only, and shall be given no substantive or
interpretative effect whatsoever.

SECTION 7.7 Severability. Any term or provision of this Agreement which is invalid or
unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of
this invalidity or unenforceability without rendering invalid or unenforceable the remaining terms
and provisions of this Agreement or affecting the validity or enforceability of any of the terms or
provisions of this Agreement in any other jurisdiction. Upon determination that any term or other
provision is invalid or incapable of being enforced, the parties shall negotiate in good faith to
modify this Agreement as to effect the original intent of the parties as closely as possible in an
acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent
possible.

SECTION 7.8 Entire Agreement. This Agreement (together with the Merger Agreement, to
the extent referred to in this Agreement) and any documents delivered by the parties in connection
herewith constitutes the entire agreement among the parties with respect to the subject matter of
this Agreement and supersedes all prior agreements and understandings among the parties with
respect thereto. No addition to or modification of any provision of this Agreement shall be
binding upon any party unless made in writing and signed by all parties.

SECTION 7.9 Assignment; Binding Effect; No Third Party Beneficiaries; Further Action.
Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned
by any of the parties. This Agreement shall be binding upon and shall inure to the benefit of
Parent and Sub and their respective successors and assigns and shall be binding upon the
Stockholders and the Stockholders’ successors, assigns, heirs, executors and administrators.
Notwithstanding anything contained in this Agreement to the contrary, nothing in this Agreement,
expressed or implied, is intended
to confer on any Person (other than, in the case of Parent and Sub, their respective
successors and assigns and, in the case of the Stockholders, the Stockholders’ successors, assigns,
heirs, executors and administrators) any rights, remedies, obligations or liabilities under or by
reason of this Agreement. The Stockholders shall take any further action and execute any other
instruments as may be reasonably requested by Parent to effectuate the intent of this Agreement.

 

-11-

 

SECTION 7.10 Mutual Drafting. Each party has participated in the drafting of this
Agreement, which each party acknowledges is the result of extensive negotiations between the
parties. This Agreement shall not be deemed to have been prepared or drafted by any one party or
another or any party’s attorneys.

SECTION 7.11 Governing Law and Consent to Jurisdiction. This Agreement shall be
governed by and construed in accordance with the laws of the State of Delaware, without regard to
its rules of conflict of laws. The Stockholders hereby irrevocably and unconditionally consent to
submit to the jurisdiction of the federal courts located in the State of Delaware or any Delaware
state courts (and, if appropriate, appellate courts therefrom) in connection with any action or
proceeding arising out of or relating to this Agreement and the transactions contemplated hereby
(and agree not to commence any suit, action or proceeding relating thereto except in those courts),
waive any defense or objection they may have or hereafter have relating to the laying of venue of
any suit, action or proceeding in any such courts and agree not to plead or claim that any suit,
action or proceeding brought therein has been brought in an inconvenient forum.

SECTION 7.12 Counterparts; Facsimiles. This Agreement may be executed by the parties
in separate counterparts, each of which when so executed and delivered shall be an original, but
all counterparts shall together constitute one and the same instrument. Each counterpart may
consist of a number of copies each signed by less than all, but together signed by all of the
parties. This Agreement or any counterpart may be executed and delivered by facsimile copies, each
of which shall be deemed an original.

(Signature page follows.)

 

-12-

 

IN WITNESS WHEREOF, Parent, Sub and the Stockholders have caused this Agreement to be duly
executed as of the day and year first above written.

	 	 	 	 	 
	 	CELGENE CORPORATION

 	 
	 	By:  	/s/  Robert J. Hugin
 	 
	 	 	Name:  	Robert J. Hugin 	 
	 	 	Title:  	Chief Executive Officer 	 
	 
	 	ARTISTRY ACQUISITION CORP.

 	 
	 	By:  	/s/  Sandesh Mahatme
 	 
	 	 	Name:  	Sandesh Mahatme 	 
	 	 	Title:  	Secretary and Treasurer 	 
	 
	 	STOCKHOLDERS:

DR. PATRICK SOON-SHIONG

 	 
	 	/s/  Dr. Patrick Soon-Shiong
 	 
	 
	 	CALIFORNIA CAPITAL LP

 	 
	 	By:  	Themba LLC, its general partner
 	 
	 	 	 
	 	By:  	                                              /s/ Steven H. Hassan
 	 
	 	 	Name:  	Steven H. Hassan 	 
	 	 	Title:  	Manager 	 
	 
	 	PATRICK SOON-SHIONG 2009 GRAT 1

 	 
	 	By:  	/s/  Patrick Soon-Shiong
 	 
	 	 	Name:  	  Patrick Soon-Shiong
	 
	 	 	Title:  	Trustee 	 

[Signature Page to Voting Agreement]

 

 

 

	 	 	 	 	 
	 	PATRICK SOON-SHIONG 2009 GRAT 2

 	 
	 	By:  	/s/  Patrick Soon-Shiong
 	 
	 	 	Name:  	Patrick Soon-Shiong 	 
	 	 	Title:  	Trustee 	 
	 
	 	MICHELE B. SOON-SHIONG GRAT 1

 	 
	 	By:  	/s/  Michele B. Chan Soon-Shiong
 	 
	 	 	Name:  	Michele B. Chan Soon-Shiong 	 
	 	 	Title:  	Trustee 	 
	 
	 	MICHELE B. SOON-SHIONG GRAT 2

 	 
	 	By:  	/s/  Michele B. Chan Soon-Shiong
 	 
	 	 	Name:  	Michele B. Chan Soon-Shiong 	 
	 	 	Title:  	Trustee 	 
	 
	 	SOON-SHIONG COMMUNITY PROPERTY REVOCABLE TRUST

 	 
	 	By:  	/s/  Patrick Soon-Shiong
 	 
	 	 	Name:  	Patrick Soon-Shiong 	 
	 	 	Title:  	Trustee 	 
	 	 	 
	 	By:  	                                              /s/  Michele B. Chan Soon-Shiong
 	 
	 	 	Name:  	Michele B. Chan Soon-Shiong 	 
	 	 	Title:  	Trustee 	 

[Signature Page to Voting Agreement]

 

 

 

	 	 	 	 	 
	 	THE CHAN SOON-SHIONG FAMILY FOUNDATION

 	 
	 	By:  	/s/  C. Kenworthy
 	 
	 	 	Name:  	C. Kenworthy 	 
	 	 	Title:  	SVP 	 

[Signature Page to Voting Agreement]

 

 

 

	 	 	 	 	 
	 	CALIFORNIA CAPITAL TRUST

 	 
	 	By:  	/s/  Patrick Soon-Shiong
 	 
	 	 	Name:  	Patrick Soon-Shiong 	 
	 	 	Title:  	Trustee 	 
	 	 	 
	 	By:  	                                              /s/  Michele B. Chan Soon-Shiong
 	 
	 	 	Name:  	Michele B. Chan Soon-Shiong 	 
	 	 	Title:  	Trustee 	 
	 	 	 
	 	By:  	                                              /s/  Steven H. Hassan
 	 
	 	 	Name:  	Steven H. Hassan 	 
	 	 	Title:  	Trustee 	 

I acknowledge that I have read the Voting Agreement, dated as of June 30, 2010, among by and among
Celgene Corporation, a Delaware corporation, Artistry Acquisition Corp., a Delaware corporation,
and the other parties thereto, and understand its contents. I am aware that by its provisions all
or part of the shares of common stock, par value $.001 per share, of Abraxis BioScience, Inc., a
Delaware corporation, held by my spouse, Dr. Patrick Soon-Shiong, including my community interest
in such shares, if any, are subject to the provisions of such agreement.

	 	 	 	 	 
	 	MICHELE B. CHAN SOON-SHIONG

 	 
	 	/s/  Michele B. Chan Soon-Shiong
 	 

[Signature Page to Voting Agreement]

 

 

 

SCHEDULE A

STOCKHOLDERS

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Stockholder	 	Owned Shares	 	 	Company Options	 	 	Company RSUs	 
	Dr. Patrick Soon-Shiong
	 	 	 	 	 	 	183,635	1	 	 	206,204	 
	Dr. Soon-Shiong may be deemed
the beneficial owner
	 	 	 	 	 	 	 	 	 	 	 	 
	California Capital LP
	 	 	7,987,159	 	 	 	 	 	 	 	 	 
	Patrick Soon-Shiong 2009 GRAT 1
	 	 	5,759,109	 	 	 	 	 	 	 	 	 
	Patrick Soon-Shiong 2009 GRAT 2
	 	 	5,759,109	 	 	 	 	 	 	 	 	 
	Michele B. Soon-Shiong GRAT 1
	 	 	5,759,109	 	 	 	 	 	 	 	 	 
	Michele B. Soon-Shiong GRAT 2
	 	 	5,759,110	 	 	 	 	 	 	 	 	 
	Soon-Shiong
Community Property Revocable Trust
	 	 	716,916	 	 	 	 	 	 	 	 	 
	California Capital Trust
	 	 	144,555	 	 	 	 	 	 	 	 	 
	The Chan
Soon-Shiong Family Foundation
	 	 	1,301,000	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	Total:
	 	 	33,186,067	 	 	 	183,635	 	 	 	206,204	 
	 	 	 	 	 	 	 	 	 	 

 

	 	 	 
	1	 	Includes 29,545 vested and 154,090 unvested Company
Options as of the date hereof.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]